Bill Text: IL SB1282 | 2015-2016 | 99th General Assembly | Introduced
Bill Title: Amends the Illinois Controlled Substances Act. Replaces the requirement that a controlled substance analog must be intended for human consumption, with the requirement that the analog is not approved by the United States Food and Drug Administration or, if approved, it is not dispensed or possessed in accordance with State and federal law. Defines "controlled substance" to include a synthetic drug enumerated as a scheduled drug under the Act. Adds chemical structural classes of synthetic cannabinoids, piperazines, and cathinones to the list of Schedule I controlled substances. Includes certain substances approved by the FDA which are not dispensed or possessed in accordance with State or federal law and certain modified substances.
Spectrum: Bipartisan Bill
Status: (Introduced - Dead) 2015-10-10 - Senate Committee Amendment No. 1 Pursuant to Senate Rule 3-9(b) / Referred to Assignments [SB1282 Detail]
Download: Illinois-2015-SB1282-Introduced.html
| |||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
1 | AN ACT concerning criminal law.
| ||||||||||||||||||||||||||||||
2 | Be it enacted by the People of the State of Illinois,
| ||||||||||||||||||||||||||||||
3 | represented in the General Assembly:
| ||||||||||||||||||||||||||||||
4 | Section 5. The Illinois Controlled Substances Act is | ||||||||||||||||||||||||||||||
5 | amended by changing Sections 102, 204, 401, and 402 as follows:
| ||||||||||||||||||||||||||||||
6 | (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102) | ||||||||||||||||||||||||||||||
7 | Sec. 102. Definitions. As used in this Act, unless the | ||||||||||||||||||||||||||||||
8 | context
otherwise requires:
| ||||||||||||||||||||||||||||||
9 | (a) "Addict" means any person who habitually uses any drug, | ||||||||||||||||||||||||||||||
10 | chemical,
substance or dangerous drug other than alcohol so as | ||||||||||||||||||||||||||||||
11 | to endanger the public
morals, health, safety or welfare or who | ||||||||||||||||||||||||||||||
12 | is so far addicted to the use of a
dangerous drug or controlled | ||||||||||||||||||||||||||||||
13 | substance other than alcohol as to have lost
the power of self | ||||||||||||||||||||||||||||||
14 | control with reference to his or her addiction.
| ||||||||||||||||||||||||||||||
15 | (b) "Administer" means the direct application of a | ||||||||||||||||||||||||||||||
16 | controlled
substance, whether by injection, inhalation, | ||||||||||||||||||||||||||||||
17 | ingestion, or any other
means, to the body of a patient, | ||||||||||||||||||||||||||||||
18 | research subject, or animal (as
defined by the Humane | ||||||||||||||||||||||||||||||
19 | Euthanasia in Animal Shelters Act) by:
| ||||||||||||||||||||||||||||||
20 | (1) a practitioner (or, in his or her presence, by his | ||||||||||||||||||||||||||||||
21 | or her authorized agent),
| ||||||||||||||||||||||||||||||
22 | (2) the patient or research subject pursuant to an | ||||||||||||||||||||||||||||||
23 | order, or
|
| |||||||
| |||||||
1 | (3) a euthanasia technician as defined by the Humane | ||||||
2 | Euthanasia in
Animal Shelters Act.
| ||||||
3 | (c) "Agent" means an authorized person who acts on behalf | ||||||
4 | of or at
the direction of a manufacturer, distributor, | ||||||
5 | dispenser, prescriber, or practitioner. It does not
include a | ||||||
6 | common or contract carrier, public warehouseman or employee of
| ||||||
7 | the carrier or warehouseman.
| ||||||
8 | (c-1) "Anabolic Steroids" means any drug or hormonal | ||||||
9 | substance,
chemically and pharmacologically related to | ||||||
10 | testosterone (other than
estrogens, progestins, | ||||||
11 | corticosteroids, and dehydroepiandrosterone),
and includes:
| ||||||
12 | (i) 3[beta],17-dihydroxy-5a-androstane, | ||||||
13 | (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, | ||||||
14 | (iii) 5[alpha]-androstan-3,17-dione, | ||||||
15 | (iv) 1-androstenediol (3[beta], | ||||||
16 | 17[beta]-dihydroxy-5[alpha]-androst-1-ene), | ||||||
17 | (v) 1-androstenediol (3[alpha], | ||||||
18 | 17[beta]-dihydroxy-5[alpha]-androst-1-ene), | ||||||
19 | (vi) 4-androstenediol | ||||||
20 | (3[beta],17[beta]-dihydroxy-androst-4-ene), | ||||||
21 | (vii) 5-androstenediol | ||||||
22 | (3[beta],17[beta]-dihydroxy-androst-5-ene), | ||||||
23 | (viii) 1-androstenedione | ||||||
24 | ([5alpha]-androst-1-en-3,17-dione), | ||||||
25 | (ix) 4-androstenedione | ||||||
26 | (androst-4-en-3,17-dione), |
| |||||||
| |||||||
1 | (x) 5-androstenedione | ||||||
2 | (androst-5-en-3,17-dione), | ||||||
3 | (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- | ||||||
4 | hydroxyandrost-4-en-3-one), | ||||||
5 | (xii) boldenone (17[beta]-hydroxyandrost- | ||||||
6 | 1,4,-diene-3-one), | ||||||
7 | (xiii) boldione (androsta-1,4- | ||||||
8 | diene-3,17-dione), | ||||||
9 | (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 | ||||||
10 | [beta]-hydroxyandrost-4-en-3-one), | ||||||
11 | (xv) clostebol (4-chloro-17[beta]- | ||||||
12 | hydroxyandrost-4-en-3-one), | ||||||
13 | (xvi) dehydrochloromethyltestosterone (4-chloro- | ||||||
14 | 17[beta]-hydroxy-17[alpha]-methyl- | ||||||
15 | androst-1,4-dien-3-one), | ||||||
16 | (xvii) desoxymethyltestosterone | ||||||
17 | (17[alpha]-methyl-5[alpha] | ||||||
18 | -androst-2-en-17[beta]-ol)(a.k.a., madol), | ||||||
19 | (xviii) [delta]1-dihydrotestosterone (a.k.a. | ||||||
20 | '1-testosterone') (17[beta]-hydroxy- | ||||||
21 | 5[alpha]-androst-1-en-3-one), | ||||||
22 | (xix) 4-dihydrotestosterone (17[beta]-hydroxy- | ||||||
23 | androstan-3-one), | ||||||
24 | (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- | ||||||
25 | 5[alpha]-androstan-3-one), | ||||||
26 | (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- |
| |||||||
| |||||||
1 | hydroxyestr-4-ene), | ||||||
2 | (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- | ||||||
3 | 1[beta],17[beta]-dihydroxyandrost-4-en-3-one), | ||||||
4 | (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], | ||||||
5 | 17[beta]-dihydroxyandrost-1,4-dien-3-one), | ||||||
6 | (xxiv) furazabol (17[alpha]-methyl-17[beta]- | ||||||
7 | hydroxyandrostano[2,3-c]-furazan), | ||||||
8 | (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one) | ||||||
9 | (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- | ||||||
10 | androst-4-en-3-one), | ||||||
11 | (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- | ||||||
12 | dihydroxy-estr-4-en-3-one), | ||||||
13 | (xxviii) mestanolone (17[alpha]-methyl-17[beta]- | ||||||
14 | hydroxy-5-androstan-3-one), | ||||||
15 | (xxix) mesterolone (1amethyl-17[beta]-hydroxy- | ||||||
16 | [5a]-androstan-3-one), | ||||||
17 | (xxx) methandienone (17[alpha]-methyl-17[beta]- | ||||||
18 | hydroxyandrost-1,4-dien-3-one), | ||||||
19 | (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- | ||||||
20 | dihydroxyandrost-5-ene), | ||||||
21 | (xxxii) methenolone (1-methyl-17[beta]-hydroxy- | ||||||
22 | 5[alpha]-androst-1-en-3-one), | ||||||
23 | (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- | ||||||
24 | dihydroxy-5a-androstane), | ||||||
25 | (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy | ||||||
26 | -5a-androstane), |
| |||||||
| |||||||
1 | (xxxv) 17[alpha]-methyl-3[beta],17[beta]- | ||||||
2 | dihydroxyandrost-4-ene), | ||||||
3 | (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- | ||||||
4 | methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), | ||||||
5 | (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- | ||||||
6 | hydroxyestra-4,9(10)-dien-3-one), | ||||||
7 | (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- | ||||||
8 | hydroxyestra-4,9-11-trien-3-one), | ||||||
9 | (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- | ||||||
10 | hydroxyandrost-4-en-3-one), | ||||||
11 | (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- | ||||||
12 | hydroxyestr-4-en-3-one), | ||||||
13 | (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone | ||||||
14 | (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- | ||||||
15 | androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- | ||||||
16 | 1-testosterone'), | ||||||
17 | (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), | ||||||
18 | (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- | ||||||
19 | dihydroxyestr-4-ene), | ||||||
20 | (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- | ||||||
21 | dihydroxyestr-4-ene), | ||||||
22 | (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- | ||||||
23 | dihydroxyestr-5-ene), | ||||||
24 | (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- | ||||||
25 | dihydroxyestr-5-ene), | ||||||
26 | (xlvii) 19-nor-4,9(10)-androstadienedione |
| |||||||
| |||||||
1 | (estra-4,9(10)-diene-3,17-dione), | ||||||
2 | (xlviii) 19-nor-4-androstenedione (estr-4- | ||||||
3 | en-3,17-dione), | ||||||
4 | (xlix) 19-nor-5-androstenedione (estr-5- | ||||||
5 | en-3,17-dione), | ||||||
6 | (l) norbolethone (13[beta], 17a-diethyl-17[beta]- | ||||||
7 | hydroxygon-4-en-3-one), | ||||||
8 | (li) norclostebol (4-chloro-17[beta]- | ||||||
9 | hydroxyestr-4-en-3-one), | ||||||
10 | (lii) norethandrolone (17[alpha]-ethyl-17[beta]- | ||||||
11 | hydroxyestr-4-en-3-one), | ||||||
12 | (liii) normethandrolone (17[alpha]-methyl-17[beta]- | ||||||
13 | hydroxyestr-4-en-3-one), | ||||||
14 | (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- | ||||||
15 | 2-oxa-5[alpha]-androstan-3-one), | ||||||
16 | (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- | ||||||
17 | dihydroxyandrost-4-en-3-one), | ||||||
18 | (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- | ||||||
19 | 17[beta]-hydroxy-(5[alpha]-androstan-3-one), | ||||||
20 | (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- | ||||||
21 | (5[alpha]-androst-2-eno[3,2-c]-pyrazole), | ||||||
22 | (lviii) stenbolone (17[beta]-hydroxy-2-methyl- | ||||||
23 | (5[alpha]-androst-1-en-3-one), | ||||||
24 | (lix) testolactone (13-hydroxy-3-oxo-13,17- | ||||||
25 | secoandrosta-1,4-dien-17-oic | ||||||
26 | acid lactone), |
| |||||||
| |||||||
1 | (lx) testosterone (17[beta]-hydroxyandrost- | ||||||
2 | 4-en-3-one), | ||||||
3 | (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- | ||||||
4 | diethyl-17[beta]-hydroxygon- | ||||||
5 | 4,9,11-trien-3-one), | ||||||
6 | (lxii) trenbolone (17[beta]-hydroxyestr-4,9, | ||||||
7 | 11-trien-3-one).
| ||||||
8 | Any person who is otherwise lawfully in possession of an | ||||||
9 | anabolic
steroid, or who otherwise lawfully manufactures, | ||||||
10 | distributes, dispenses,
delivers, or possesses with intent to | ||||||
11 | deliver an anabolic steroid, which
anabolic steroid is | ||||||
12 | expressly intended for and lawfully allowed to be
administered | ||||||
13 | through implants to livestock or other nonhuman species, and
| ||||||
14 | which is approved by the Secretary of Health and Human Services | ||||||
15 | for such
administration, and which the person intends to | ||||||
16 | administer or have
administered through such implants, shall | ||||||
17 | not be considered to be in
unauthorized possession or to | ||||||
18 | unlawfully manufacture, distribute, dispense,
deliver, or | ||||||
19 | possess with intent to deliver such anabolic steroid for
| ||||||
20 | purposes of this Act.
| ||||||
21 | (d) "Administration" means the Drug Enforcement | ||||||
22 | Administration,
United States Department of Justice, or its | ||||||
23 | successor agency.
| ||||||
24 | (d-5) "Clinical Director, Prescription Monitoring Program" | ||||||
25 | means a Department of Human Services administrative employee | ||||||
26 | licensed to either prescribe or dispense controlled substances |
| |||||||
| |||||||
1 | who shall run the clinical aspects of the Department of Human | ||||||
2 | Services Prescription Monitoring Program and its Prescription | ||||||
3 | Information Library. | ||||||
4 | (d-10) "Compounding" means the preparation and mixing of | ||||||
5 | components, excluding flavorings, (1) as the result of a | ||||||
6 | prescriber's prescription drug order or initiative based on the | ||||||
7 | prescriber-patient-pharmacist relationship in the course of | ||||||
8 | professional practice or (2) for the purpose of, or incident | ||||||
9 | to, research, teaching, or chemical analysis and not for sale | ||||||
10 | or dispensing. "Compounding" includes the preparation of drugs | ||||||
11 | or devices in anticipation of receiving prescription drug | ||||||
12 | orders based on routine, regularly observed dispensing | ||||||
13 | patterns. Commercially available products may be compounded | ||||||
14 | for dispensing to individual patients only if both of the | ||||||
15 | following conditions are met: (i) the commercial product is not | ||||||
16 | reasonably available from normal distribution channels in a | ||||||
17 | timely manner to meet the patient's needs and (ii) the | ||||||
18 | prescribing practitioner has requested that the drug be | ||||||
19 | compounded. | ||||||
20 | (e) "Control" means to add a drug or other substance, or | ||||||
21 | immediate
precursor, to a Schedule whether by
transfer from | ||||||
22 | another Schedule or otherwise.
| ||||||
23 | (f) "Controlled Substance" means (i) a drug, substance, or | ||||||
24 | immediate
precursor , or synthetic drug in the Schedules of | ||||||
25 | Article II of this Act or (ii) a drug or other substance, or | ||||||
26 | immediate precursor, designated as a controlled substance by |
| |||||||
| |||||||
1 | the Department through administrative rule. The term does not | ||||||
2 | include distilled spirits, wine, malt beverages, or tobacco, as | ||||||
3 | those terms are
defined or used in the Liquor Control Act of | ||||||
4 | 1934 and the Tobacco Products Tax
Act of 1995.
| ||||||
5 | (f-5) "Controlled substance analog" means a substance: | ||||||
6 | (1) the chemical structure of which is substantially | ||||||
7 | similar to the chemical structure of a controlled substance | ||||||
8 | in Schedule I or II; | ||||||
9 | (2) which has a stimulant, depressant, or | ||||||
10 | hallucinogenic effect on the central nervous system that is | ||||||
11 | substantially similar to or greater than the stimulant, | ||||||
12 | depressant, or hallucinogenic effect on the central | ||||||
13 | nervous system of a controlled substance in Schedule I or | ||||||
14 | II; or | ||||||
15 | (3) with respect to a particular person, which such | ||||||
16 | person represents or intends to have a stimulant, | ||||||
17 | depressant, or hallucinogenic effect on the central | ||||||
18 | nervous system that is substantially similar to or greater | ||||||
19 | than the stimulant, depressant, or hallucinogenic effect | ||||||
20 | on the central nervous system of a controlled substance in | ||||||
21 | Schedule I or II. | ||||||
22 | (g) "Counterfeit substance" means a controlled substance, | ||||||
23 | which, or
the container or labeling of which, without | ||||||
24 | authorization bears the
trademark, trade name, or other | ||||||
25 | identifying mark, imprint, number or
device, or any likeness | ||||||
26 | thereof, of a manufacturer, distributor, or
dispenser other |
| |||||||
| |||||||
1 | than the person who in fact manufactured, distributed,
or | ||||||
2 | dispensed the substance.
| ||||||
3 | (h) "Deliver" or "delivery" means the actual, constructive | ||||||
4 | or
attempted transfer of possession of a controlled substance, | ||||||
5 | with or
without consideration, whether or not there is an | ||||||
6 | agency relationship.
| ||||||
7 | (i) "Department" means the Illinois Department of Human | ||||||
8 | Services (as
successor to the Department of Alcoholism and | ||||||
9 | Substance Abuse) or its successor agency.
| ||||||
10 | (j) (Blank).
| ||||||
11 | (k) "Department of Corrections" means the Department of | ||||||
12 | Corrections
of the State of Illinois or its successor agency.
| ||||||
13 | (l) "Department of Financial and Professional Regulation" | ||||||
14 | means the Department
of Financial and Professional Regulation | ||||||
15 | of the State of Illinois or its successor agency.
| ||||||
16 | (m) "Depressant" means any drug that (i) causes an overall | ||||||
17 | depression of central nervous system functions, (ii) causes | ||||||
18 | impaired consciousness and awareness, and (iii) can be | ||||||
19 | habit-forming or lead to a substance abuse problem, including | ||||||
20 | but not limited to alcohol, cannabis and its active principles | ||||||
21 | and their analogs, benzodiazepines and their analogs, | ||||||
22 | barbiturates and their analogs, opioids (natural and | ||||||
23 | synthetic) and their analogs, and chloral hydrate and similar | ||||||
24 | sedative hypnotics.
| ||||||
25 | (n) (Blank).
| ||||||
26 | (o) "Director" means the Director of the Illinois State |
| |||||||
| |||||||
1 | Police or his or her designated agents.
| ||||||
2 | (p) "Dispense" means to deliver a controlled substance to | ||||||
3 | an
ultimate user or research subject by or pursuant to the | ||||||
4 | lawful order of
a prescriber, including the prescribing, | ||||||
5 | administering, packaging,
labeling, or compounding necessary | ||||||
6 | to prepare the substance for that
delivery.
| ||||||
7 | (q) "Dispenser" means a practitioner who dispenses.
| ||||||
8 | (r) "Distribute" means to deliver, other than by | ||||||
9 | administering or
dispensing, a controlled substance.
| ||||||
10 | (s) "Distributor" means a person who distributes.
| ||||||
11 | (t) "Drug" means (1) substances recognized as drugs in the | ||||||
12 | official
United States Pharmacopoeia, Official Homeopathic | ||||||
13 | Pharmacopoeia of the
United States, or official National | ||||||
14 | Formulary, or any supplement to any
of them; (2) substances | ||||||
15 | intended for use in diagnosis, cure, mitigation,
treatment, or | ||||||
16 | prevention of disease in man or animals; (3) substances
(other | ||||||
17 | than food) intended to affect the structure of any function of
| ||||||
18 | the body of man or animals and (4) substances intended for use | ||||||
19 | as a
component of any article specified in clause (1), (2), or | ||||||
20 | (3) of this
subsection. It does not include devices or their | ||||||
21 | components, parts, or
accessories.
| ||||||
22 | (t-5) "Euthanasia agency" means
an entity certified by the | ||||||
23 | Department of Financial and Professional Regulation for the
| ||||||
24 | purpose of animal euthanasia that holds an animal control | ||||||
25 | facility license or
animal
shelter license under the Animal | ||||||
26 | Welfare Act. A euthanasia agency is
authorized to purchase, |
| |||||||
| |||||||
1 | store, possess, and utilize Schedule II nonnarcotic and
| ||||||
2 | Schedule III nonnarcotic drugs for the sole purpose of animal | ||||||
3 | euthanasia.
| ||||||
4 | (t-10) "Euthanasia drugs" means Schedule II or Schedule III | ||||||
5 | substances
(nonnarcotic controlled substances) that are used | ||||||
6 | by a euthanasia agency for
the purpose of animal euthanasia.
| ||||||
7 | (u) "Good faith" means the prescribing or dispensing of a | ||||||
8 | controlled
substance by a practitioner in the regular course of | ||||||
9 | professional
treatment to or for any person who is under his or | ||||||
10 | her treatment for a
pathology or condition other than that | ||||||
11 | individual's physical or
psychological dependence upon or | ||||||
12 | addiction to a controlled substance,
except as provided herein: | ||||||
13 | and application of the term to a pharmacist
shall mean the | ||||||
14 | dispensing of a controlled substance pursuant to the
| ||||||
15 | prescriber's order which in the professional judgment of the | ||||||
16 | pharmacist
is lawful. The pharmacist shall be guided by | ||||||
17 | accepted professional
standards including, but not limited to | ||||||
18 | the following, in making the
judgment:
| ||||||
19 | (1) lack of consistency of prescriber-patient | ||||||
20 | relationship,
| ||||||
21 | (2) frequency of prescriptions for same drug by one | ||||||
22 | prescriber for
large numbers of patients,
| ||||||
23 | (3) quantities beyond those normally prescribed,
| ||||||
24 | (4) unusual dosages (recognizing that there may be | ||||||
25 | clinical circumstances where more or less than the usual | ||||||
26 | dose may be used legitimately),
|
| |||||||
| |||||||
1 | (5) unusual geographic distances between patient, | ||||||
2 | pharmacist and
prescriber,
| ||||||
3 | (6) consistent prescribing of habit-forming drugs.
| ||||||
4 | (u-0.5) "Hallucinogen" means a drug that causes markedly | ||||||
5 | altered sensory perception leading to hallucinations of any | ||||||
6 | type. | ||||||
7 | (u-1) "Home infusion services" means services provided by a | ||||||
8 | pharmacy in
compounding solutions for direct administration to | ||||||
9 | a patient in a private
residence, long-term care facility, or | ||||||
10 | hospice setting by means of parenteral,
intravenous, | ||||||
11 | intramuscular, subcutaneous, or intraspinal infusion.
| ||||||
12 | (u-5) "Illinois State Police" means the State
Police of the | ||||||
13 | State of Illinois, or its successor agency. | ||||||
14 | (v) "Immediate precursor" means a substance:
| ||||||
15 | (1) which the Department has found to be and by rule | ||||||
16 | designated as
being a principal compound used, or produced | ||||||
17 | primarily for use, in the
manufacture of a controlled | ||||||
18 | substance;
| ||||||
19 | (2) which is an immediate chemical intermediary used or | ||||||
20 | likely to
be used in the manufacture of such controlled | ||||||
21 | substance; and
| ||||||
22 | (3) the control of which is necessary to prevent, | ||||||
23 | curtail or limit
the manufacture of such controlled | ||||||
24 | substance.
| ||||||
25 | (w) "Instructional activities" means the acts of teaching, | ||||||
26 | educating
or instructing by practitioners using controlled |
| |||||||
| |||||||
1 | substances within
educational facilities approved by the State | ||||||
2 | Board of Education or
its successor agency.
| ||||||
3 | (x) "Local authorities" means a duly organized State, | ||||||
4 | County or
Municipal peace unit or police force.
| ||||||
5 | (y) "Look-alike substance" means a substance, other than a | ||||||
6 | controlled
substance which (1) by overall dosage unit | ||||||
7 | appearance, including shape,
color, size, markings or lack | ||||||
8 | thereof, taste, consistency, or any other
identifying physical | ||||||
9 | characteristic of the substance, would lead a reasonable
person | ||||||
10 | to believe that the substance is a controlled substance, or (2) | ||||||
11 | is
expressly or impliedly represented to be a controlled | ||||||
12 | substance or is
distributed under circumstances which would | ||||||
13 | lead a reasonable person to
believe that the substance is a | ||||||
14 | controlled substance. For the purpose of
determining whether | ||||||
15 | the representations made or the circumstances of the
| ||||||
16 | distribution would lead a reasonable person to believe the | ||||||
17 | substance to be
a controlled substance under this clause (2) of | ||||||
18 | subsection (y), the court or
other authority may consider the | ||||||
19 | following factors in addition to any other
factor that may be | ||||||
20 | relevant:
| ||||||
21 | (a) statements made by the owner or person in control | ||||||
22 | of the substance
concerning its nature, use or effect;
| ||||||
23 | (b) statements made to the buyer or recipient that the | ||||||
24 | substance may
be resold for profit;
| ||||||
25 | (c) whether the substance is packaged in a manner | ||||||
26 | normally used for the
illegal distribution of controlled |
| |||||||
| |||||||
1 | substances;
| ||||||
2 | (d) whether the distribution or attempted distribution | ||||||
3 | included an
exchange of or demand for money or other | ||||||
4 | property as consideration, and
whether the amount of the | ||||||
5 | consideration was substantially greater than the
| ||||||
6 | reasonable retail market value of the substance.
| ||||||
7 | Clause (1) of this subsection (y) shall not apply to a | ||||||
8 | noncontrolled
substance in its finished dosage form that was | ||||||
9 | initially introduced into
commerce prior to the initial | ||||||
10 | introduction into commerce of a controlled
substance in its | ||||||
11 | finished dosage form which it may substantially resemble.
| ||||||
12 | Nothing in this subsection (y) prohibits the dispensing or | ||||||
13 | distributing
of noncontrolled substances by persons authorized | ||||||
14 | to dispense and
distribute controlled substances under this | ||||||
15 | Act, provided that such action
would be deemed to be carried | ||||||
16 | out in good faith under subsection (u) if the
substances | ||||||
17 | involved were controlled substances.
| ||||||
18 | Nothing in this subsection (y) or in this Act prohibits the | ||||||
19 | manufacture,
preparation, propagation, compounding, | ||||||
20 | processing, packaging, advertising
or distribution of a drug or | ||||||
21 | drugs by any person registered pursuant to
Section 510 of the | ||||||
22 | Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
| ||||||
23 | (y-1) "Mail-order pharmacy" means a pharmacy that is | ||||||
24 | located in a state
of the United States that delivers, | ||||||
25 | dispenses or
distributes, through the United States Postal | ||||||
26 | Service or other common
carrier, to Illinois residents, any |
| |||||||
| |||||||
1 | substance which requires a prescription.
| ||||||
2 | (z) "Manufacture" means the production, preparation, | ||||||
3 | propagation,
compounding, conversion or processing of a | ||||||
4 | controlled substance other than methamphetamine, either
| ||||||
5 | directly or indirectly, by extraction from substances of | ||||||
6 | natural origin,
or independently by means of chemical | ||||||
7 | synthesis, or by a combination of
extraction and chemical | ||||||
8 | synthesis, and includes any packaging or
repackaging of the | ||||||
9 | substance or labeling of its container, except that
this term | ||||||
10 | does not include:
| ||||||
11 | (1) by an ultimate user, the preparation or compounding | ||||||
12 | of a
controlled substance for his or her own use; or
| ||||||
13 | (2) by a practitioner, or his or her authorized agent | ||||||
14 | under his or her
supervision, the preparation, | ||||||
15 | compounding, packaging, or labeling of a
controlled | ||||||
16 | substance:
| ||||||
17 | (a) as an incident to his or her administering or | ||||||
18 | dispensing of a
controlled substance in the course of | ||||||
19 | his or her professional practice; or
| ||||||
20 | (b) as an incident to lawful research, teaching or | ||||||
21 | chemical
analysis and not for sale.
| ||||||
22 | (z-1) (Blank).
| ||||||
23 | (z-5) "Medication shopping" means the conduct prohibited | ||||||
24 | under subsection (a) of Section 314.5 of this Act. | ||||||
25 | (z-10) "Mid-level practitioner" means (i) a physician | ||||||
26 | assistant who has been delegated authority to prescribe through |
| |||||||
| |||||||
1 | a written delegation of authority by a physician licensed to | ||||||
2 | practice medicine in all of its branches, in accordance with | ||||||
3 | Section 7.5 of the Physician Assistant Practice Act of 1987, | ||||||
4 | (ii) an advanced practice nurse who has been delegated | ||||||
5 | authority to prescribe through a written delegation of | ||||||
6 | authority by a physician licensed to practice medicine in all | ||||||
7 | of its branches or by a podiatric physician, in accordance with | ||||||
8 | Section 65-40 of the Nurse Practice Act, (iii) an animal | ||||||
9 | euthanasia agency, or (iv) a prescribing psychologist. | ||||||
10 | (aa) "Narcotic drug" means any of the following, whether | ||||||
11 | produced
directly or indirectly by extraction from substances | ||||||
12 | of vegetable origin,
or independently by means of chemical | ||||||
13 | synthesis, or by a combination of
extraction and chemical | ||||||
14 | synthesis:
| ||||||
15 | (1) opium, opiates, derivatives of opium and opiates, | ||||||
16 | including their isomers, esters, ethers, salts, and salts | ||||||
17 | of isomers, esters, and ethers, whenever the existence of | ||||||
18 | such isomers, esters, ethers, and salts is possible within | ||||||
19 | the specific chemical designation; however the term | ||||||
20 | "narcotic drug" does not include the isoquinoline | ||||||
21 | alkaloids of opium;
| ||||||
22 | (2) (blank);
| ||||||
23 | (3) opium poppy and poppy straw;
| ||||||
24 | (4) coca leaves, except coca leaves and extracts of | ||||||
25 | coca leaves from which substantially all of the cocaine and | ||||||
26 | ecgonine, and their isomers, derivatives and salts, have |
| |||||||
| |||||||
1 | been removed;
| ||||||
2 | (5) cocaine, its salts, optical and geometric isomers, | ||||||
3 | and salts of isomers; | ||||||
4 | (6) ecgonine, its derivatives, their salts, isomers, | ||||||
5 | and salts of isomers; | ||||||
6 | (7) any compound, mixture, or preparation which | ||||||
7 | contains any quantity of any of the substances referred to | ||||||
8 | in subparagraphs (1) through (6). | ||||||
9 | (bb) "Nurse" means a registered nurse licensed under the
| ||||||
10 | Nurse Practice Act.
| ||||||
11 | (cc) (Blank).
| ||||||
12 | (dd) "Opiate" means any substance having an addiction | ||||||
13 | forming or
addiction sustaining liability similar to morphine | ||||||
14 | or being capable of
conversion into a drug having addiction | ||||||
15 | forming or addiction sustaining
liability.
| ||||||
16 | (ee) "Opium poppy" means the plant of the species Papaver
| ||||||
17 | somniferum L., except its seeds.
| ||||||
18 | (ee-5) "Oral dosage" means a tablet, capsule, elixir, or | ||||||
19 | solution or other liquid form of medication intended for | ||||||
20 | administration by mouth, but the term does not include a form | ||||||
21 | of medication intended for buccal, sublingual, or transmucosal | ||||||
22 | administration. | ||||||
23 | (ff) "Parole and Pardon Board" means the Parole and Pardon | ||||||
24 | Board of
the State of Illinois or its successor agency.
| ||||||
25 | (gg) "Person" means any individual, corporation, | ||||||
26 | mail-order pharmacy,
government or governmental subdivision or |
| |||||||
| |||||||
1 | agency, business trust, estate,
trust, partnership or | ||||||
2 | association, or any other entity.
| ||||||
3 | (hh) "Pharmacist" means any person who holds a license or | ||||||
4 | certificate of
registration as a registered pharmacist, a local | ||||||
5 | registered pharmacist
or a registered assistant pharmacist | ||||||
6 | under the Pharmacy Practice Act.
| ||||||
7 | (ii) "Pharmacy" means any store, ship or other place in | ||||||
8 | which
pharmacy is authorized to be practiced under the Pharmacy | ||||||
9 | Practice Act.
| ||||||
10 | (ii-5) "Pharmacy shopping" means the conduct prohibited | ||||||
11 | under subsection (b) of Section 314.5 of this Act. | ||||||
12 | (ii-10) "Physician" (except when the context otherwise | ||||||
13 | requires) means a person licensed to practice medicine in all | ||||||
14 | of its branches. | ||||||
15 | (jj) "Poppy straw" means all parts, except the seeds, of | ||||||
16 | the opium
poppy, after mowing.
| ||||||
17 | (kk) "Practitioner" means a physician licensed to practice | ||||||
18 | medicine in all
its branches, dentist, optometrist, podiatric | ||||||
19 | physician,
veterinarian, scientific investigator, pharmacist, | ||||||
20 | physician assistant,
advanced practice nurse,
licensed | ||||||
21 | practical
nurse, registered nurse, hospital, laboratory, or | ||||||
22 | pharmacy, or other
person licensed, registered, or otherwise | ||||||
23 | lawfully permitted by the
United States or this State to | ||||||
24 | distribute, dispense, conduct research
with respect to, | ||||||
25 | administer or use in teaching or chemical analysis, a
| ||||||
26 | controlled substance in the course of professional practice or |
| |||||||
| |||||||
1 | research.
| ||||||
2 | (ll) "Pre-printed prescription" means a written | ||||||
3 | prescription upon which
the designated drug has been indicated | ||||||
4 | prior to the time of issuance; the term does not mean a written | ||||||
5 | prescription that is individually generated by machine or | ||||||
6 | computer in the prescriber's office.
| ||||||
7 | (mm) "Prescriber" means a physician licensed to practice | ||||||
8 | medicine in all
its branches, dentist, optometrist, | ||||||
9 | prescribing psychologist licensed under Section 4.2 of the | ||||||
10 | Clinical Psychologist Licensing Act with prescriptive | ||||||
11 | authority delegated under Section 4.3 of the Clinical | ||||||
12 | Psychologist Licensing Act, podiatric physician, or
| ||||||
13 | veterinarian who issues a prescription, a physician assistant | ||||||
14 | who
issues a
prescription for a controlled substance
in | ||||||
15 | accordance
with Section 303.05, a written delegation, and a | ||||||
16 | written supervision agreement required under Section 7.5
of the
| ||||||
17 | Physician Assistant Practice Act of 1987, or an advanced | ||||||
18 | practice
nurse with prescriptive authority delegated under | ||||||
19 | Section 65-40 of the Nurse Practice Act and in accordance with | ||||||
20 | Section 303.05, a written delegation,
and a written
| ||||||
21 | collaborative agreement under Section 65-35 of the Nurse | ||||||
22 | Practice Act.
| ||||||
23 | (nn) "Prescription" means a written, facsimile, or oral | ||||||
24 | order, or an electronic order that complies with applicable | ||||||
25 | federal requirements,
of
a physician licensed to practice | ||||||
26 | medicine in all its branches,
dentist, podiatric physician or |
| |||||||
| |||||||
1 | veterinarian for any controlled
substance, of an optometrist | ||||||
2 | for a Schedule II, III, IV, or V controlled substance in | ||||||
3 | accordance with Section 15.1 of the Illinois Optometric | ||||||
4 | Practice Act of 1987, of a prescribing psychologist licensed | ||||||
5 | under Section 4.2 of the Clinical Psychologist Licensing Act | ||||||
6 | with prescriptive authority delegated under Section 4.3 of the | ||||||
7 | Clinical Psychologist Licensing Act, of a physician assistant | ||||||
8 | for a
controlled substance
in accordance with Section 303.05, a | ||||||
9 | written delegation, and a written supervision agreement | ||||||
10 | required under
Section 7.5 of the
Physician Assistant Practice | ||||||
11 | Act of 1987, or of an advanced practice
nurse with prescriptive | ||||||
12 | authority delegated under Section 65-40 of the Nurse Practice | ||||||
13 | Act who issues a prescription for a
controlled substance in | ||||||
14 | accordance
with
Section 303.05, a written delegation, and a | ||||||
15 | written collaborative agreement under Section 65-35 of the | ||||||
16 | Nurse Practice Act when required by law.
| ||||||
17 | (nn-5) "Prescription Information Library" (PIL) means an | ||||||
18 | electronic library that contains reported controlled substance | ||||||
19 | data. | ||||||
20 | (nn-10) "Prescription Monitoring Program" (PMP) means the | ||||||
21 | entity that collects, tracks, and stores reported data on | ||||||
22 | controlled substances and select drugs pursuant to Section 316. | ||||||
23 | (oo) "Production" or "produce" means manufacture, | ||||||
24 | planting,
cultivating, growing, or harvesting of a controlled | ||||||
25 | substance other than methamphetamine.
| ||||||
26 | (pp) "Registrant" means every person who is required to |
| |||||||
| |||||||
1 | register
under Section 302 of this Act.
| ||||||
2 | (qq) "Registry number" means the number assigned to each | ||||||
3 | person
authorized to handle controlled substances under the | ||||||
4 | laws of the United
States and of this State.
| ||||||
5 | (qq-5) "Secretary" means, as the context requires, either | ||||||
6 | the Secretary of the Department or the Secretary of the | ||||||
7 | Department of Financial and Professional Regulation, and the | ||||||
8 | Secretary's designated agents. | ||||||
9 | (rr) "State" includes the State of Illinois and any state, | ||||||
10 | district,
commonwealth, territory, insular possession thereof, | ||||||
11 | and any area
subject to the legal authority of the United | ||||||
12 | States of America.
| ||||||
13 | (rr-5) "Stimulant" means any drug that (i) causes an | ||||||
14 | overall excitation of central nervous system functions, (ii) | ||||||
15 | causes impaired consciousness and awareness, and (iii) can be | ||||||
16 | habit-forming or lead to a substance abuse problem, including | ||||||
17 | but not limited to amphetamines and their analogs, | ||||||
18 | methylphenidate and its analogs, cocaine, and phencyclidine | ||||||
19 | and its analogs. | ||||||
20 | (rr-10) "Synthetic drug" includes, but is not limited to, | ||||||
21 | any synthetic cannabinoids or piperazines or any synthetic | ||||||
22 | cathinones as provided for in Schedule I. | ||||||
23 | (ss) "Ultimate user" means a person who lawfully possesses | ||||||
24 | a
controlled substance for his or her own use or for the use of | ||||||
25 | a member of his or her
household or for administering to an | ||||||
26 | animal owned by him or her or by a member
of his or her |
| |||||||
| |||||||
1 | household.
| ||||||
2 | (Source: P.A. 97-334, eff. 1-1-12; 98-214, eff. 8-9-13; 98-668, | ||||||
3 | eff. 6-25-14; 98-756, eff. 7-16-14; 98-1111, eff. 8-26-14; | ||||||
4 | revised 10-1-14.)
| ||||||
5 | (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) | ||||||
6 | Sec. 204. (a) The controlled substances listed in this | ||||||
7 | Section are
included in Schedule I. | ||||||
8 | (b) Unless specifically excepted or unless listed in | ||||||
9 | another
schedule, any of the following opiates, including their | ||||||
10 | isomers,
esters, ethers, salts, and salts of isomers, esters, | ||||||
11 | and ethers,
whenever the existence of such isomers, esters, | ||||||
12 | ethers and salts is
possible within the specific chemical | ||||||
13 | designation: | ||||||
14 | (1) Acetylmethadol; | ||||||
15 | (1.1) Acetyl-alpha-methylfentanyl | ||||||
16 | (N-[1-(1-methyl-2-phenethyl)-
| ||||||
17 | 4-piperidinyl]-N-phenylacetamide); | ||||||
18 | (2) Allylprodine; | ||||||
19 | (3) Alphacetylmethadol, except
| ||||||
20 | levo-alphacetylmethadol (also known as levo-alpha-
| ||||||
21 | acetylmethadol, levomethadyl acetate, or LAAM); | ||||||
22 | (4) Alphameprodine; | ||||||
23 | (5) Alphamethadol; | ||||||
24 | (6) Alpha-methylfentanyl
| ||||||
25 | (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
|
| |||||||
| |||||||
1 | propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
| ||||||
2 | propanilido) piperidine; | ||||||
3 | (6.1) Alpha-methylthiofentanyl
| ||||||
4 | (N-[1-methyl-2-(2-thienyl)ethyl-
| ||||||
5 | 4-piperidinyl]-N-phenylpropanamide); | ||||||
6 | (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); | ||||||
7 | (7.1) PEPAP
| ||||||
8 | (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); | ||||||
9 | (8) Benzethidine; | ||||||
10 | (9) Betacetylmethadol; | ||||||
11 | (9.1) Beta-hydroxyfentanyl
| ||||||
12 | (N-[1-(2-hydroxy-2-phenethyl)-
| ||||||
13 | 4-piperidinyl]-N-phenylpropanamide); | ||||||
14 | (10) Betameprodine; | ||||||
15 | (11) Betamethadol; | ||||||
16 | (12) Betaprodine; | ||||||
17 | (13) Clonitazene; | ||||||
18 | (14) Dextromoramide; | ||||||
19 | (15) Diampromide; | ||||||
20 | (16) Diethylthiambutene; | ||||||
21 | (17) Difenoxin; | ||||||
22 | (18) Dimenoxadol; | ||||||
23 | (19) Dimepheptanol; | ||||||
24 | (20) Dimethylthiambutene; | ||||||
25 | (21) Dioxaphetylbutyrate; | ||||||
26 | (22) Dipipanone; |
| |||||||
| |||||||
1 | (23) Ethylmethylthiambutene; | ||||||
2 | (24) Etonitazene; | ||||||
3 | (25) Etoxeridine; | ||||||
4 | (26) Furethidine; | ||||||
5 | (27) Hydroxpethidine; | ||||||
6 | (28) Ketobemidone; | ||||||
7 | (29) Levomoramide; | ||||||
8 | (30) Levophenacylmorphan; | ||||||
9 | (31) 3-Methylfentanyl
| ||||||
10 | (N-[3-methyl-1-(2-phenylethyl)-
| ||||||
11 | 4-piperidyl]-N-phenylpropanamide); | ||||||
12 | (31.1) 3-Methylthiofentanyl
| ||||||
13 | (N-[(3-methyl-1-(2-thienyl)ethyl-
| ||||||
14 | 4-piperidinyl]-N-phenylpropanamide); | ||||||
15 | (32) Morpheridine; | ||||||
16 | (33) Noracymethadol; | ||||||
17 | (34) Norlevorphanol; | ||||||
18 | (35) Normethadone; | ||||||
19 | (36) Norpipanone; | ||||||
20 | (36.1) Para-fluorofentanyl
| ||||||
21 | (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
| ||||||
22 | 4-piperidinyl]propanamide); | ||||||
23 | (37) Phenadoxone; | ||||||
24 | (38) Phenampromide; | ||||||
25 | (39) Phenomorphan; | ||||||
26 | (40) Phenoperidine; |
| |||||||
| |||||||
1 | (41) Piritramide; | ||||||
2 | (42) Proheptazine; | ||||||
3 | (43) Properidine; | ||||||
4 | (44) Propiram; | ||||||
5 | (45) Racemoramide; | ||||||
6 | (45.1) Thiofentanyl
| ||||||
7 | (N-phenyl-N-[1-(2-thienyl)ethyl-
| ||||||
8 | 4-piperidinyl]-propanamide); | ||||||
9 | (46) Tilidine; | ||||||
10 | (47) Trimeperidine; | ||||||
11 | (48) Beta-hydroxy-3-methylfentanyl (other name:
| ||||||
12 | N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
| ||||||
13 | N-phenylpropanamide). | ||||||
14 | (c) Unless specifically excepted or unless listed in | ||||||
15 | another
schedule, any of the following opium derivatives, its | ||||||
16 | salts, isomers
and salts of isomers, whenever the existence of | ||||||
17 | such salts, isomers and
salts of isomers is possible within the | ||||||
18 | specific chemical designation: | ||||||
19 | (1) Acetorphine; | ||||||
20 | (2) Acetyldihydrocodeine; | ||||||
21 | (3) Benzylmorphine; | ||||||
22 | (4) Codeine methylbromide; | ||||||
23 | (5) Codeine-N-Oxide; | ||||||
24 | (6) Cyprenorphine; | ||||||
25 | (7) Desomorphine; | ||||||
26 | (8) Diacetyldihydromorphine (Dihydroheroin); |
| |||||||
| |||||||
1 | (9) Dihydromorphine; | ||||||
2 | (10) Drotebanol; | ||||||
3 | (11) Etorphine (except hydrochloride salt); | ||||||
4 | (12) Heroin; | ||||||
5 | (13) Hydromorphinol; | ||||||
6 | (14) Methyldesorphine; | ||||||
7 | (15) Methyldihydromorphine; | ||||||
8 | (16) Morphine methylbromide; | ||||||
9 | (17) Morphine methylsulfonate; | ||||||
10 | (18) Morphine-N-Oxide; | ||||||
11 | (19) Myrophine; | ||||||
12 | (20) Nicocodeine; | ||||||
13 | (21) Nicomorphine; | ||||||
14 | (22) Normorphine; | ||||||
15 | (23) Pholcodine; | ||||||
16 | (24) Thebacon. | ||||||
17 | (d) Unless specifically excepted or unless listed in | ||||||
18 | another
schedule, any material, compound, mixture, or | ||||||
19 | preparation which contains
any quantity of the following | ||||||
20 | hallucinogenic substances, or which
contains any of its salts, | ||||||
21 | isomers and salts of isomers, whenever the
existence of such | ||||||
22 | salts, isomers, and salts of isomers is possible
within the | ||||||
23 | specific chemical designation (for the purposes of this
| ||||||
24 | paragraph only, the term "isomer" includes the optical, | ||||||
25 | position and
geometric isomers): | ||||||
26 | (1) 3,4-methylenedioxyamphetamine
|
| |||||||
| |||||||
1 | (alpha-methyl,3,4-methylenedioxyphenethylamine,
| ||||||
2 | methylenedioxyamphetamine, MDA); | ||||||
3 | (1.1) Alpha-ethyltryptamine
| ||||||
4 | (some trade or other names: etryptamine;
| ||||||
5 | MONASE; alpha-ethyl-1H-indole-3-ethanamine;
| ||||||
6 | 3-(2-aminobutyl)indole; a-ET; and AET); | ||||||
7 | (2) 3,4-methylenedioxymethamphetamine (MDMA); | ||||||
8 | (2.1) 3,4-methylenedioxy-N-ethylamphetamine
| ||||||
9 | (also known as: N-ethyl-alpha-methyl-
| ||||||
10 | 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
| ||||||
11 | and MDEA); | ||||||
12 | (2.2) N-Benzylpiperazine (BZP); | ||||||
13 | (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); | ||||||
14 | (4) 3,4,5-trimethoxyamphetamine (TMA); | ||||||
15 | (5) (Blank); | ||||||
16 | (6) Diethyltryptamine (DET); | ||||||
17 | (7) Dimethyltryptamine (DMT); | ||||||
18 | (7.1) 5-Methoxy-diallyltryptamine; | ||||||
19 | (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); | ||||||
20 | (9) Ibogaine (some trade and other names:
| ||||||
21 | 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
| ||||||
22 | 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
| ||||||
23 | indole; Tabernanthe iboga); | ||||||
24 | (10) Lysergic acid diethylamide; | ||||||
25 | (10.1) Salvinorin A; | ||||||
26 | (10.5) Salvia divinorum (meaning all parts of the plant |
| |||||||
| |||||||
1 | presently classified
botanically as Salvia divinorum, | ||||||
2 | whether growing or not, the
seeds thereof, any extract from | ||||||
3 | any part of that plant, and every compound,
manufacture, | ||||||
4 | salts, isomers, and salts of
isomers whenever the existence | ||||||
5 | of such salts, isomers, and salts of
isomers is possible | ||||||
6 | within the specific chemical designation, derivative, | ||||||
7 | mixture, or preparation of that plant, its
seeds or | ||||||
8 | extracts);
| ||||||
9 | (11) 3,4,5-trimethoxyphenethylamine (Mescaline); | ||||||
10 | (12) Peyote (meaning all parts of the plant presently | ||||||
11 | classified
botanically as Lophophora williamsii
Lemaire, | ||||||
12 | whether growing or not, the
seeds thereof, any extract from | ||||||
13 | any part of that plant, and every compound,
manufacture, | ||||||
14 | salts, derivative, mixture, or preparation of that plant, | ||||||
15 | its
seeds or extracts); | ||||||
16 | (13) N-ethyl-3-piperidyl benzilate (JB 318); | ||||||
17 | (14) N-methyl-3-piperidyl benzilate; | ||||||
18 | (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
| ||||||
19 | (also known as N-hydroxy-alpha-methyl-
| ||||||
20 | 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); | ||||||
21 | (15) Parahexyl; some trade or other names:
| ||||||
22 | 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
| ||||||
23 | dibenzo (b,d) pyran; Synhexyl; | ||||||
24 | (16) Psilocybin; | ||||||
25 | (17) Psilocyn; | ||||||
26 | (18) Alpha-methyltryptamine (AMT); |
| |||||||
| |||||||
1 | (19) 2,5-dimethoxyamphetamine
| ||||||
2 | (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | ||||||
3 | (20) 4-bromo-2,5-dimethoxyamphetamine
| ||||||
4 | (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
| ||||||
5 | 4-bromo-2,5-DMA); | ||||||
6 | (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
| ||||||
7 | Some trade or other names: 2-(4-bromo-
| ||||||
8 | 2,5-dimethoxyphenyl)-1-aminoethane;
| ||||||
9 | alpha-desmethyl DOB, 2CB, Nexus; | ||||||
10 | (21) 4-methoxyamphetamine
| ||||||
11 | (4-methoxy-alpha-methylphenethylamine;
| ||||||
12 | paramethoxyamphetamine; PMA); | ||||||
13 | (22) (Blank); | ||||||
14 | (23) Ethylamine analog of phencyclidine.
| ||||||
15 | Some trade or other names:
| ||||||
16 | N-ethyl-1-phenylcyclohexylamine,
| ||||||
17 | (1-phenylcyclohexyl) ethylamine,
| ||||||
18 | N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; | ||||||
19 | (24) Pyrrolidine analog of phencyclidine. Some trade | ||||||
20 | or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, | ||||||
21 | PHP; | ||||||
22 | (25) 5-methoxy-3,4-methylenedioxy-amphetamine; | ||||||
23 | (26) 2,5-dimethoxy-4-ethylamphetamine
| ||||||
24 | (another name: DOET); | ||||||
25 | (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
| ||||||
26 | (another name: TCPy); |
| |||||||
| |||||||
1 | (28) (Blank); | ||||||
2 | (29) Thiophene analog of phencyclidine (some trade
| ||||||
3 | or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
| ||||||
4 | 2-thienyl analog of phencyclidine; TPCP; TCP); | ||||||
5 | (30) Bufotenine (some trade or other names:
| ||||||
6 | 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
| ||||||
7 | 3-(2-dimethylaminoethyl)-5-indolol;
| ||||||
8 | 5-hydroxy-N,N-dimethyltryptamine;
| ||||||
9 | N,N-dimethylserotonin; mappine); | ||||||
10 | (31) 1-Pentyl-3-(1-naphthoyl)indole | ||||||
11 | Some trade or other names: JWH-018; | ||||||
12 | (32) 1-Butyl-3-(1-naphthoyl)indole | ||||||
13 | Some trade or other names: JWH-073; | ||||||
14 | (33) 1-[(5-fluoropentyl)-1H-indol-3-yl]- | ||||||
15 | (2-iodophenyl)methanone | ||||||
16 | Some trade or other names: AM-694; | ||||||
17 | (34) 2-[(1R,3S)-3-hydroxycyclohexyl]-5- | ||||||
18 | (2-methyloctan-2-yl)phenol | ||||||
19 | Some trade or other names: CP 47,497 | ||||||
20 | and its C6, C8 and C9 homologs; | ||||||
21 | (34.5) 2-[(1R,3S)-3-hydroxycyclohexyl]-5- | ||||||
22 | (2-methyloctan-2-yl)phenol), where side chain n=5; | ||||||
23 | and homologues where side chain n=4, 6, or 7; Some | ||||||
24 | trade or other names: CP 47,497; | ||||||
25 | (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- | ||||||
26 | (2-methyloctan-2-yl)-6a,7, |
| |||||||
| |||||||
1 | 10,10a-tetrahydrobenzo[c]chromen-1-ol | ||||||
2 | Some trade or other names: HU-210; | ||||||
3 | (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- | ||||||
4 | dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- | ||||||
5 | tetrahydrobenzo[c]chromen-1-ol, its isomers, | ||||||
6 | salts, and salts of isomers; Some trade or other | ||||||
7 | names: HU-210, Dexanabinol; | ||||||
8 | (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- | ||||||
9 | 6,6-dimethyl-3-(2-methyloctan-2-yl)- | ||||||
10 | 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | ||||||
11 | Some trade or other names: HU-211; | ||||||
12 | (37) (2-methyl-1-propyl-1H-indol- | ||||||
13 | 3-yl)-1-naphthalenyl-methanone | ||||||
14 | Some trade or other names: JWH-015; | ||||||
15 | (38) 4-methoxynaphthalen-1-yl- | ||||||
16 | (1-pentylindol-3-yl)methanone | ||||||
17 | Some trade or other names: JWH-081; | ||||||
18 | (39) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole | ||||||
19 | Some trade or other names: JWH-122; | ||||||
20 | (40) 2-(2-methylphenyl)-1-(1-pentyl- | ||||||
21 | 1H-indol-3-yl)-ethanone | ||||||
22 | Some trade or other names: JWH-251; | ||||||
23 | (41) 1-(2-cyclohexylethyl)-3- | ||||||
24 | (2-methoxyphenylacetyl)indole | ||||||
25 | Some trade or other names: RCS-8, BTW-8 and SR-18; | ||||||
26 | (42) Any compound structurally derived from |
| |||||||
| |||||||
1 | 3-(1-naphthoyl)indole or 1H-indol-3-yl- | ||||||
2 | (1-naphthyl)methane by substitution at the | ||||||
3 | nitrogen atom of the indole ring by alkyl, haloalkyl, | ||||||
4 | alkenyl, cycloalkylmethyl, cycloalkylethyl or | ||||||
5 | 2-(4-morpholinyl)ethyl whether or not further | ||||||
6 | substituted in the indole ring to any extent, whether | ||||||
7 | or not substituted in the naphthyl ring to any extent; | ||||||
8 | (43) Any compound structurally derived from | ||||||
9 | 3-(1-naphthoyl)pyrrole by substitution at the nitrogen | ||||||
10 | atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, | ||||||
11 | cycloalkylmethyl, cycloalkylethyl or | ||||||
12 | 2-(4-morpholinyl)ethyl, whether or not further | ||||||
13 | substituted in the pyrrole ring to any extent, whether | ||||||
14 | or not substituted in the naphthyl ring to any extent; | ||||||
15 | (44) Any compound structurally derived from | ||||||
16 | 1-(1-naphthylmethyl)indene by substitution | ||||||
17 | at the 3-position of the indene ring by alkyl, haloalkyl, | ||||||
18 | alkenyl, cycloalkylmethyl, cycloalkylethyl or | ||||||
19 | 2-(4-morpholinyl)ethyl whether or not further | ||||||
20 | substituted in the indene ring to any extent, whether | ||||||
21 | or not substituted in the naphthyl ring to any extent; | ||||||
22 | (45) Any compound structurally derived from | ||||||
23 | 3-phenylacetylindole by substitution at the | ||||||
24 | nitrogen atom of the indole ring with alkyl, haloalkyl, | ||||||
25 | alkenyl, cycloalkylmethyl, cycloalkylethyl or | ||||||
26 | 2-(4-morpholinyl)ethyl, whether or not further |
| |||||||
| |||||||
1 | substituted in the indole ring to any extent, whether | ||||||
2 | or not substituted in the phenyl ring to any extent; | ||||||
3 | (46) Any compound structurally derived from | ||||||
4 | 2-(3-hydroxycyclohexyl)phenol by substitution | ||||||
5 | at the 5-position of the phenolic ring by alkyl, | ||||||
6 | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl | ||||||
7 | or 2-(4-morpholinyl)ethyl, whether or not substituted | ||||||
8 | in the cyclohexyl ring to any extent; | ||||||
9 | (47) 3,4-Methylenedioxymethcathinone | ||||||
10 | Some trade or other names: Methylone; | ||||||
11 | (48) 3,4-Methyenedioxypyrovalerone | ||||||
12 | Some trade or other names: MDPV; | ||||||
13 | (49) 4-Methylmethcathinone | ||||||
14 | Some trade or other names: Mephedrone; | ||||||
15 | (50) 4-methoxymethcathinone; | ||||||
16 | (51) 4-Fluoromethcathinone; | ||||||
17 | (52) 3-Fluoromethcathinone; | ||||||
18 | (53) 2,5-Dimethoxy-4-(n)-propylthio- | ||||||
19 | phenethylamine; | ||||||
20 | (54) 5-Methoxy-N,N-diisopropyltryptamine; | ||||||
21 | (55) Pentedrone; | ||||||
22 | (56) 4-iodo-2,5-dimethoxy-N-((2-methoxy | ||||||
23 | phenyl)methyl)-benzeneethanamine | ||||||
24 | (trade or other name: 25I-NBOMe); | ||||||
25 | (57) 4-chloro-2,5-dimethoxy-N-[(2-methoxyphenyl) | ||||||
26 | methyl]-benzeneethanamine (trade or other name: |
| |||||||
| |||||||
1 | 25C-NBOMe); | ||||||
2 | (58) 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl) | ||||||
3 | methyl]-benzeneethanamine (trade or other name: | ||||||
4 | 25B-NBOMe). | ||||||
5 | (e) Unless specifically excepted or unless listed in | ||||||
6 | another
schedule, any material, compound, mixture, or | ||||||
7 | preparation which contains
any quantity of the following | ||||||
8 | substances having a depressant effect on
the central nervous | ||||||
9 | system, including its salts, isomers, and salts of
isomers | ||||||
10 | whenever the existence of such salts, isomers, and salts of
| ||||||
11 | isomers is possible within the specific chemical designation: | ||||||
12 | (1) mecloqualone; | ||||||
13 | (2) methaqualone; and | ||||||
14 | (3) gamma hydroxybutyric acid. | ||||||
15 | (f) Unless specifically excepted or unless listed in | ||||||
16 | another schedule,
any material, compound, mixture, or | ||||||
17 | preparation which contains any quantity
of the following | ||||||
18 | substances having a stimulant effect on the central nervous
| ||||||
19 | system, including its salts, isomers, and salts of isomers: | ||||||
20 | (1) Fenethylline; | ||||||
21 | (2) N-ethylamphetamine; | ||||||
22 | (3) Aminorex (some other names:
| ||||||
23 | 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
| ||||||
24 | 4-5-dihydro-5-phenyl-2-oxazolamine) and its
| ||||||
25 | salts, optical isomers, and salts of optical isomers; | ||||||
26 | (4) Methcathinone (some other names:
|
| |||||||
| |||||||
1 | 2-methylamino-1-phenylpropan-1-one;
| ||||||
2 | Ephedrone; 2-(methylamino)-propiophenone;
| ||||||
3 | alpha-(methylamino)propiophenone; N-methylcathinone;
| ||||||
4 | methycathinone; Monomethylpropion; UR 1431) and its
| ||||||
5 | salts, optical isomers, and salts of optical isomers; | ||||||
6 | (5) Cathinone (some trade or other names:
| ||||||
7 | 2-aminopropiophenone; alpha-aminopropiophenone;
| ||||||
8 | 2-amino-1-phenyl-propanone; norephedrone); | ||||||
9 | (6) N,N-dimethylamphetamine (also known as:
| ||||||
10 | N,N-alpha-trimethyl-benzeneethanamine;
| ||||||
11 | N,N-alpha-trimethylphenethylamine); | ||||||
12 | (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
| ||||||
13 | 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); | ||||||
14 | (8) 3,4-Methylenedioxypyrovalerone (MDPV). | ||||||
15 | (g) Temporary listing of substances subject to emergency | ||||||
16 | scheduling.
Any material, compound, mixture, or preparation | ||||||
17 | that contains any quantity
of the following substances: | ||||||
18 | (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
| ||||||
19 | (benzylfentanyl), its optical isomers, isomers, salts,
| ||||||
20 | and salts of isomers; | ||||||
21 | (2) N-[1(2-thienyl)
| ||||||
22 | methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
| ||||||
23 | its optical isomers, salts, and salts of isomers. | ||||||
24 | (h) Synthetic cannabinoids or piperazines. Unless | ||||||
25 | specifically excepted, any chemical compound which is not | ||||||
26 | approved by the United States Food and Drug Administration or, |
| |||||||
| |||||||
1 | if approved, which is not dispensed or possessed in accordance | ||||||
2 | with State and federal law, that contains: | ||||||
3 | (1) Benzylpiperazine (BZP); | ||||||
4 | (2) Trifluoromethylphenylpiperazine (TFMPP); | ||||||
5 | (3) 1,1- | ||||||
6 | Dimethylheptyl-11-hydroxytetrahydrocannabinol | ||||||
7 | (HU-210); 1-Butyl-3-(1-naphthoyl) indole; 1- | ||||||
8 | Pentyl-3-(1-naphthoyl) indole; | ||||||
9 | (4) dexanabinol (HU-211); or | ||||||
10 | (5) any compound in the following | ||||||
11 | structural classes: | ||||||
12 | (A) Naphthylmethylindoles: Any compound | ||||||
13 | containing a 1H-indol-3-yl-(1-naphthyl) methane | ||||||
14 | structure with substitution at the nitrogen | ||||||
15 | atom of the indole ring by an alkyl, haloalkyl, | ||||||
16 | alkenyl, cycloalkylmethyl, cycloalkylethyl, | ||||||
17 | 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
18 | 2-(4-morpholinyl)ethyl group whether or not | ||||||
19 | further substituted in the indole ring to any extent | ||||||
20 | and whether or not substituted in the naphthyl ring | ||||||
21 | to any extent. Examples of this structural class | ||||||
22 | include, but are not limited to, JWH-175, JWH-184, | ||||||
23 | and JWH-185; | ||||||
24 | (B) Phenylacetylindoles: Any compound | ||||||
25 | containing a 3-phenylacetylindole structure | ||||||
26 | with substitution at the nitrogen atom of the |
| |||||||
| |||||||
1 | indole ring by an alkyl, haloalkyl, alkenyl, | ||||||
2 | cycloalkylmethyl, cycloalkylethyl, | ||||||
3 | 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
4 | 2-(4-morpholinyl)ethyl group whether or not | ||||||
5 | further substituted in the indole ring | ||||||
6 | to any extent and whether or not substituted | ||||||
7 | in the phenyl ring to any extent. Examples of | ||||||
8 | this structural class include, but are not | ||||||
9 | limited to, JWH-167, JWH-250, JWH-251, and RCS-8; | ||||||
10 | (C) Benzoylindoles: Any compound | ||||||
11 | containing a 3-(benzoyl) indole structure with | ||||||
12 | substitution at the nitrogen atom of the | ||||||
13 | indole ring by an alkyl, haloalkyl, alkenyl, | ||||||
14 | cycloalkylmethyl, cycloalkylethyl, | ||||||
15 | 1-(N-methyl-2-piperidinyl)methyl, | ||||||
16 | or 2-(4-morpholinyl)ethyl group | ||||||
17 | whether or not further substituted | ||||||
18 | in the indole ring to any extent and | ||||||
19 | whether or not substituted in the phenyl ring | ||||||
20 | to any extent. Examples of this structural class | ||||||
21 | include, but are not limited, to AM-630, | ||||||
22 | AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4; | ||||||
23 | (D) Cyclohexylphenols: Any compound | ||||||
24 | containing a 2-(3-hydroxycyclohexyl)phenol | ||||||
25 | structure with substitution at the 5-position | ||||||
26 | of the phenolic ring by an alkyl, haloalkyl, |
| |||||||
| |||||||
1 | alkenyl, cycloalkylmethyl, cycloalkylethyl, | ||||||
2 | 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
3 | 2-(4-morpholinyl)ethyl group whether or | ||||||
4 | not substituted in the cyclohexyl ring to | ||||||
5 | any extent. Examples of this structural | ||||||
6 | class include, but are not limited to, | ||||||
7 | CP 47,497 and its C8 homologue | ||||||
8 | (cannabicyclohexanol); | ||||||
9 | (E) Naphthylmethylindoles: Any compound | ||||||
10 | containing a 1H-indol-3-yl-(1-naphthyl) methane | ||||||
11 | structure with substitution at the nitrogen atom of | ||||||
12 | the indole ring by an alkyl, haloalkyl, alkenyl, | ||||||
13 | cycloalkylmethyl, cycloalkylethyl, | ||||||
14 | 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
15 | 2-(4-morpholinyl)ethyl group whether | ||||||
16 | or not further substituted in the indole | ||||||
17 | ring to any extent and whether or not | ||||||
18 | substituted in the naphthyl ring to any extent. | ||||||
19 | Examples of this structural class include, | ||||||
20 | but are not limited to, JWH-175, JWH-184, | ||||||
21 | and JWH-185; | ||||||
22 | (F) Naphthoylpyrroles: Any compound | ||||||
23 | containing a 3-(1-naphthoyl)pyrrole structure | ||||||
24 | with substitution at the nitrogen atom of | ||||||
25 | the pyrrole ring by an alkyl, haloalkyl, alkenyl, | ||||||
26 | cycloalkylmethyl, cycloalkylethyl, |
| |||||||
| |||||||
1 | 1-(N-methyl-2-piperidinyl)methyl, or | ||||||
2 | 2-(4-morpholinyl)ethyl group whether | ||||||
3 | or not further substituted in the pyrrole ring | ||||||
4 | to any extent and whether or not substituted | ||||||
5 | in the naphthyl ring to any extent. Examples | ||||||
6 | of this structural class include, but are not | ||||||
7 | limited, to JWH-030, JWH-145, JWH-146, JWH-307, | ||||||
8 | and JWH-368; | ||||||
9 | (G) Naphthylmethylindenes: Any compound | ||||||
10 | containing a 1-(1-naphthylmethyl)indene structure | ||||||
11 | with substitution at the 3-position of the indene | ||||||
12 | ring by an alkyl, haloalkyl, alkenyl, | ||||||
13 | cycloalkylmethyl, cycloalkylethyl, | ||||||
14 | 1-(N-methyl-2-piperidinyl)methyl, | ||||||
15 | or 2-(4-morpholinyl)ethyl group whether or | ||||||
16 | not further substituted in the indene ring | ||||||
17 | to any extent and whether or not substituted in | ||||||
18 | the naphthyl ring to any extent. Examples of this | ||||||
19 | structural class include, but are not limited | ||||||
20 | to, JWH-176; or | ||||||
21 | (H) Any other synthetic cannabinoid | ||||||
22 | or piperazine which is not approved by the United | ||||||
23 | States Food and Drug Administration or, if | ||||||
24 | approved, which is not dispensed or possessed | ||||||
25 | in accordance with State and federal law. | ||||||
26 | (i) Synthetic cathinones. Unless specifically excepted, |
| |||||||
| |||||||
1 | any chemical compound which is not approved by the United | ||||||
2 | States Food and Drug Administration or, if approved, which is | ||||||
3 | not dispensed or possessed in accordance with State and federal | ||||||
4 | law, not including bupropion, structurally derived from | ||||||
5 | 2-aminopropan-1-one by substitution at the 1-position with | ||||||
6 | either phenyl, naphthyl, or thiophene ring systems, whether or | ||||||
7 | not the compound is further modified in one or more of the | ||||||
8 | following ways: | ||||||
9 | (1) By substitution in the ring system to | ||||||
10 | any extent with alkyl, alkylenedioxy, alkoxy, | ||||||
11 | haloalkyl, hydroxyl, or halide substituents, whether | ||||||
12 | or not further substituted in the ring system | ||||||
13 | by one or more other univalent substituents. | ||||||
14 | Examples of this class include, but are not | ||||||
15 | limited to, 3,4-Methylenedioxycathinone | ||||||
16 | (bk-MDA); | ||||||
17 | (2) By substitution at the 3-position | ||||||
18 | with an acyclic alkyl substituent. Examples of | ||||||
19 | this class include, but are not limited to, | ||||||
20 | 2-methylamino-1-phenylbutan-1-one | ||||||
21 | (buphedrone); | ||||||
22 | (3) By substitution at the 2-amino nitrogen | ||||||
23 | atom with alkyl, dialkyl, benzyl, or methoxybenzyl | ||||||
24 | groups, or by inclusion of the 2-amino nitrogen atom | ||||||
25 | in a cyclic structure. Examples of this class include, | ||||||
26 | but are not limited to, Dimethylcathinone, Ethcathinone, |
| |||||||
| |||||||
1 | and a-Pyrrolidinopropiophenone (a-PPP); or | ||||||
2 | (4) Any other synthetic cathinone | ||||||
3 | which is not approved by the United States Food and Drug | ||||||
4 | Administration or, if approved, is not dispensed or | ||||||
5 | possessed in accordance with State or federal law. | ||||||
6 | (Source: P.A. 97-192, eff. 7-22-11; 97-193, eff. 1-1-12; | ||||||
7 | 97-194, eff. 7-22-11; 97-334, eff. 1-1-12; 97-813, eff. | ||||||
8 | 7-13-12; 97-872, eff. 7-31-12; 98-987, eff. 1-1-15 .)
| ||||||
9 | (720 ILCS 570/401) (from Ch. 56 1/2, par. 1401)
| ||||||
10 | Sec. 401. Except as authorized by this Act, it is unlawful | ||||||
11 | for any
person knowingly to manufacture or deliver, or possess | ||||||
12 | with intent to
manufacture or deliver, a controlled substance | ||||||
13 | other than methamphetamine, a counterfeit substance, or a | ||||||
14 | controlled
substance analog. A violation of this Act with | ||||||
15 | respect to each of the controlled
substances listed herein | ||||||
16 | constitutes a single and separate violation of this
Act. For | ||||||
17 | purposes of this Section, "controlled substance analog" or | ||||||
18 | "analog"
means a substance
which is intended for human | ||||||
19 | consumption , other than a controlled substance, which is not | ||||||
20 | approved by the United States Food and Drug Administration or, | ||||||
21 | if approved, is not dispensed or possessed in accordance with | ||||||
22 | State or federal law, and
that has a chemical structure | ||||||
23 | substantially similar to that of a controlled
substance in | ||||||
24 | Schedule I or II, or that was specifically designed to produce
| ||||||
25 | an effect substantially similar to that of a controlled |
| |||||||
| |||||||
1 | substance in Schedule
I or II. Examples of chemical classes in | ||||||
2 | which controlled substance analogs
are found include, but are | ||||||
3 | not limited to, the following: phenethylamines,
N-substituted | ||||||
4 | piperidines, morphinans, ecgonines, quinazolinones, | ||||||
5 | substituted
indoles, and arylcycloalkylamines. For purposes of | ||||||
6 | this Act, a controlled
substance analog shall be treated in the | ||||||
7 | same manner as the controlled
substance to which it is | ||||||
8 | substantially similar.
| ||||||
9 | (a) Any person who violates this Section with respect to | ||||||
10 | the following
amounts of controlled or counterfeit substances | ||||||
11 | or controlled substance
analogs, notwithstanding any of the | ||||||
12 | provisions of subsections (c),
(d), (e), (f), (g) or (h) to the | ||||||
13 | contrary, is guilty of a Class X felony
and shall be sentenced | ||||||
14 | to a term of imprisonment as provided in this subsection
(a) | ||||||
15 | and fined as provided in subsection (b):
| ||||||
16 | (1) (A) not less than 6 years and not more than 30 | ||||||
17 | years with respect
to 15 grams or more but less than | ||||||
18 | 100 grams of a substance containing
heroin, or an | ||||||
19 | analog thereof;
| ||||||
20 | (B) not less than 9 years and not more than 40 | ||||||
21 | years with respect to 100
grams or more but less than | ||||||
22 | 400 grams of a substance containing heroin, or
an | ||||||
23 | analog thereof;
| ||||||
24 | (C) not less than 12 years and not more than 50 | ||||||
25 | years with respect to
400 grams or more but less than | ||||||
26 | 900 grams of a substance containing heroin,
or an |
| |||||||
| |||||||
1 | analog thereof;
| ||||||
2 | (D) not less than 15 years and not more than 60 | ||||||
3 | years with respect to
900 grams or more of any | ||||||
4 | substance containing heroin, or an analog thereof;
| ||||||
5 | (1.5) (A) not less than 6 years and not more than 30 | ||||||
6 | years with respect to 15 grams or more but less than | ||||||
7 | 100 grams of a substance containing fentanyl, or an | ||||||
8 | analog thereof;
| ||||||
9 | (B) not less than 9 years and not more than 40 | ||||||
10 | years with respect to 100 grams or more but less than | ||||||
11 | 400 grams of a substance containing fentanyl, or an | ||||||
12 | analog thereof; | ||||||
13 | (C) not less than 12 years and not more than 50 | ||||||
14 | years with respect to 400 grams or more but less than | ||||||
15 | 900 grams of a substance containing fentanyl, or an | ||||||
16 | analog thereof; | ||||||
17 | (D) not less than 15 years and not more than 60 | ||||||
18 | years with respect to 900 grams or more of a substance | ||||||
19 | containing fentanyl, or an analog thereof;
| ||||||
20 | (2) (A) not less than 6 years and not more than 30 | ||||||
21 | years with respect
to 15 grams or more but less than | ||||||
22 | 100 grams of a substance containing
cocaine, or an | ||||||
23 | analog thereof;
| ||||||
24 | (B) not less than 9 years and not more than 40 | ||||||
25 | years with respect to 100
grams or more but less than | ||||||
26 | 400 grams of a substance containing cocaine, or
an |
| |||||||
| |||||||
1 | analog thereof;
| ||||||
2 | (C) not less than 12 years and not more than 50 | ||||||
3 | years with respect to
400 grams or more but less than | ||||||
4 | 900 grams of a substance containing cocaine,
or an | ||||||
5 | analog thereof;
| ||||||
6 | (D) not less than 15 years and not more than 60 | ||||||
7 | years with respect to
900 grams or more of any | ||||||
8 | substance containing cocaine, or an analog thereof;
| ||||||
9 | (3) (A) not less than 6 years and not more than 30 | ||||||
10 | years with respect
to 15 grams or more but less than | ||||||
11 | 100 grams of a substance containing
morphine, or an | ||||||
12 | analog thereof;
| ||||||
13 | (B) not less than 9 years and not more than 40 | ||||||
14 | years with respect to
100 grams or more but less than | ||||||
15 | 400 grams of a substance containing morphine,
or an | ||||||
16 | analog thereof;
| ||||||
17 | (C) not less than 12 years and not more than 50 | ||||||
18 | years with respect to
400 grams or more but less than | ||||||
19 | 900 grams of a substance containing
morphine, or an | ||||||
20 | analog thereof;
| ||||||
21 | (D) not less than 15 years and not more than 60 | ||||||
22 | years with respect to
900 grams or more of a substance | ||||||
23 | containing morphine, or an analog thereof;
| ||||||
24 | (4) 200 grams or more of any substance containing | ||||||
25 | peyote, or an
analog thereof;
| ||||||
26 | (5) 200 grams or more of any substance containing a |
| |||||||
| |||||||
1 | derivative of
barbituric acid or any of the salts of a | ||||||
2 | derivative of barbituric acid, or
an analog thereof;
| ||||||
3 | (6) 200 grams or more of any substance containing | ||||||
4 | amphetamine
or any salt of an optical isomer of | ||||||
5 | amphetamine,
or an analog thereof;
| ||||||
6 | (6.5) (blank);
| ||||||
7 | (6.6) (blank);
| ||||||
8 | (7) (A) not less than 6 years and not more than 30 | ||||||
9 | years with respect
to: (i) 15 grams or more but less | ||||||
10 | than 100 grams of a substance containing
lysergic acid | ||||||
11 | diethylamide (LSD), or an analog thereof, or (ii) 15 or
| ||||||
12 | more objects or 15 or more segregated parts of an | ||||||
13 | object or objects but
less than 200 objects or 200 | ||||||
14 | segregated parts of an object or objects
containing in | ||||||
15 | them or having upon them any amounts of any substance
| ||||||
16 | containing lysergic acid diethylamide (LSD), or an | ||||||
17 | analog thereof;
| ||||||
18 | (B) not less than 9 years and not more than 40 | ||||||
19 | years with respect
to: (i) 100 grams or more but less | ||||||
20 | than 400 grams of a substance containing
lysergic acid | ||||||
21 | diethylamide (LSD), or an analog thereof, or (ii) 200 | ||||||
22 | or more
objects or 200 or more segregated parts of an | ||||||
23 | object or objects but less
than 600 objects or less | ||||||
24 | than 600 segregated parts of an object or objects
| ||||||
25 | containing in them or having upon them any amount of | ||||||
26 | any substance
containing lysergic acid diethylamide |
| |||||||
| |||||||
1 | (LSD), or an analog thereof;
| ||||||
2 | (C) not less than 12 years and not more than 50 | ||||||
3 | years with respect
to: (i) 400 grams or more but less | ||||||
4 | than 900 grams of a substance containing
lysergic acid | ||||||
5 | diethylamide (LSD), or an analog thereof, or (ii) 600 | ||||||
6 | or more
objects or 600 or more segregated parts of an | ||||||
7 | object or objects but less
than 1500 objects or 1500 | ||||||
8 | segregated parts of an object or objects
containing in | ||||||
9 | them or having upon them any amount of any substance
| ||||||
10 | containing lysergic acid diethylamide (LSD), or an | ||||||
11 | analog thereof;
| ||||||
12 | (D) not less than 15 years and not more than 60 | ||||||
13 | years with respect
to: (i) 900 grams or more of any | ||||||
14 | substance containing lysergic acid
diethylamide (LSD), | ||||||
15 | or an analog thereof, or (ii) 1500 or more objects or
| ||||||
16 | 1500 or more segregated parts of an object or objects | ||||||
17 | containing in them or
having upon them any amount of a | ||||||
18 | substance containing lysergic acid
diethylamide (LSD), | ||||||
19 | or an analog thereof;
| ||||||
20 | (7.5) (A) not less than 6 years and not more than 30 | ||||||
21 | years with respect
to:
(i) 15
grams or more but less | ||||||
22 | than 100 grams of a substance listed in paragraph (1),
| ||||||
23 | (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1), | ||||||
24 | (21), (25), or (26) of subsection
(d) of Section 204, | ||||||
25 | or an analog or derivative thereof, or (ii) 15 or more
| ||||||
26 | pills, tablets, caplets, capsules, or objects but less |
| |||||||
| |||||||
1 | than 200 pills, tablets,
caplets, capsules, or objects | ||||||
2 | containing in them or having upon them any
amounts of | ||||||
3 | any substance listed in paragraph (1), (2), (2.1), | ||||||
4 | (2.2), (3), (14.1),
(19), (20), (20.1), (21), (25), or | ||||||
5 | (26) of subsection (d) of Section 204, or
an analog or | ||||||
6 | derivative thereof;
| ||||||
7 | (B) not less than 9 years and not more than 40 | ||||||
8 | years with respect to:
(i) 100 grams or more but less | ||||||
9 | than 400 grams of a substance listed in
paragraph (1), | ||||||
10 | (2), (2.1), (2.2), (3), (14.1), (19), (20),
(20.1), | ||||||
11 | (21), (25), or (26) of subsection (d) of Section 204, | ||||||
12 | or an analog or
derivative thereof, or (ii) 200 or more | ||||||
13 | pills, tablets, caplets, capsules, or
objects but less | ||||||
14 | than 600 pills, tablets, caplets, capsules, or objects
| ||||||
15 | containing in them or having upon them any amount of | ||||||
16 | any substance listed in
paragraph (1), (2), (2.1), | ||||||
17 | (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or | ||||||
18 | (26)
of subsection (d) of Section 204, or an analog or | ||||||
19 | derivative thereof;
| ||||||
20 | (C) not less than 12 years and not more than 50 | ||||||
21 | years with respect to:
(i) 400 grams or more but less | ||||||
22 | than 900 grams of a substance listed in
paragraph (1), | ||||||
23 | (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1), | ||||||
24 | (21), (25), or (26)
of subsection (d) of Section 204, | ||||||
25 | or an analog or derivative thereof,
or (ii) 600 or more | ||||||
26 | pills, tablets, caplets, capsules, or objects but less |
| |||||||
| |||||||
1 | than
1,500 pills, tablets, caplets, capsules, or | ||||||
2 | objects
containing in them or having upon them any | ||||||
3 | amount of any substance listed in
paragraph (1), (2), | ||||||
4 | (2.1), (2.2), (3), (14.1), (19), (20), (20.1), (21), | ||||||
5 | (25), or (26)
of subsection (d) of Section 204, or an | ||||||
6 | analog or derivative thereof;
| ||||||
7 | (D) not less than 15 years and not more than 60 | ||||||
8 | years with respect to:
(i) 900 grams or more of any | ||||||
9 | substance listed in paragraph (1), (2), (2.1),
(2.2), | ||||||
10 | (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of | ||||||
11 | subsection (d) of
Section 204, or an analog or | ||||||
12 | derivative thereof, or (ii) 1,500 or more pills,
| ||||||
13 | tablets, caplets, capsules, or objects containing in | ||||||
14 | them or having upon them
any amount
of a substance | ||||||
15 | listed in paragraph (1), (2), (2.1), (2.2), (3), | ||||||
16 | (14.1), (19),
(20), (20.1), (21), (25), or (26)
of | ||||||
17 | subsection (d) of Section 204, or an analog or | ||||||
18 | derivative thereof;
| ||||||
19 | (8) 30 grams or more of any substance containing | ||||||
20 | pentazocine or any of
the salts, isomers and salts of | ||||||
21 | isomers of pentazocine, or an analog thereof;
| ||||||
22 | (9) 30 grams or more of any substance containing | ||||||
23 | methaqualone or any of
the salts, isomers and salts of | ||||||
24 | isomers of methaqualone, or an analog thereof;
| ||||||
25 | (10) 30 grams or more of any substance containing | ||||||
26 | phencyclidine or any
of the salts, isomers and salts of |
| |||||||
| |||||||
1 | isomers of phencyclidine (PCP),
or an analog thereof;
| ||||||
2 | (10.5) 30 grams or more of any substance containing | ||||||
3 | ketamine
or any of the salts, isomers and salts of isomers | ||||||
4 | of ketamine,
or an analog thereof;
| ||||||
5 | (10.6) 100 grams or more of any substance containing | ||||||
6 | hydrocodone, or any of the salts, isomers and salts of | ||||||
7 | isomers of hydrocodone, or an analog thereof; | ||||||
8 | (10.7) 100 grams or more of any substance containing | ||||||
9 | dihydrocodeinone, or any of the salts, isomers and salts of | ||||||
10 | isomers of dihydrocodeinone, or an analog thereof; | ||||||
11 | (10.8) 100 grams or more of any substance containing | ||||||
12 | dihydrocodeine, or any of the salts, isomers and salts of | ||||||
13 | isomers of dihydrocodeine, or an analog thereof; | ||||||
14 | (10.9) 100 grams or more of any substance containing | ||||||
15 | oxycodone, or any of the salts, isomers and salts of | ||||||
16 | isomers of oxycodone, or an analog thereof;
| ||||||
17 | (11) 200 grams or more of any substance containing any | ||||||
18 | other controlled
substance classified in Schedules I or II, | ||||||
19 | or an analog thereof, which is
not otherwise included in | ||||||
20 | this subsection.
| ||||||
21 | (b) Any person sentenced with respect to violations of | ||||||
22 | paragraph (1),
(2), (3), (7), or (7.5) of subsection (a) | ||||||
23 | involving
100 grams or
more of the
controlled substance named | ||||||
24 | therein, may in addition to the penalties
provided therein, be | ||||||
25 | fined an amount not more than $500,000 or the full
street value | ||||||
26 | of the controlled or counterfeit substance or controlled |
| |||||||
| |||||||
1 | substance
analog, whichever is greater. The term "street value" | ||||||
2 | shall have the
meaning ascribed in Section 110-5 of the Code of | ||||||
3 | Criminal Procedure of
1963. Any person sentenced with respect | ||||||
4 | to any other provision of
subsection (a), may in addition to | ||||||
5 | the penalties provided therein, be fined
an amount not to | ||||||
6 | exceed $500,000. | ||||||
7 | (b-1) Excluding violations of this Act when the controlled | ||||||
8 | substance is fentanyl, any person sentenced to a term of | ||||||
9 | imprisonment with respect to violations of Section 401, 401.1, | ||||||
10 | 405, 405.1, 405.2, or 407, when the substance containing the | ||||||
11 | controlled substance contains any amount of fentanyl, 3 years | ||||||
12 | shall be added to the term of imprisonment imposed by the | ||||||
13 | court, and the maximum sentence for the offense shall be | ||||||
14 | increased by 3 years.
| ||||||
15 | (c) Any person who violates this Section with regard to the
| ||||||
16 | following amounts of controlled or counterfeit substances
or | ||||||
17 | controlled substance analogs, notwithstanding any of the | ||||||
18 | provisions of
subsections (a), (b), (d), (e), (f), (g) or (h) | ||||||
19 | to the
contrary, is guilty of a Class 1 felony. The fine for | ||||||
20 | violation of this
subsection (c) shall not be more than | ||||||
21 | $250,000:
| ||||||
22 | (1) 1 gram or more but less than 15 grams of any
| ||||||
23 | substance containing heroin, or an analog thereof;
| ||||||
24 | (1.5) 1 gram or more but less than 15 grams of any | ||||||
25 | substance containing fentanyl, or an analog thereof;
| ||||||
26 | (2) 1 gram or more but less than 15
grams of any |
| |||||||
| |||||||
1 | substance containing cocaine, or an analog thereof;
| ||||||
2 | (3) 10 grams or more but less than 15 grams of any | ||||||
3 | substance
containing morphine, or an analog thereof;
| ||||||
4 | (4) 50 grams or more but less than 200 grams of any | ||||||
5 | substance
containing peyote, or an analog thereof;
| ||||||
6 | (5) 50 grams or more but less than 200 grams of any | ||||||
7 | substance
containing a derivative of barbituric acid or any | ||||||
8 | of the salts of a
derivative of barbituric acid, or an | ||||||
9 | analog thereof;
| ||||||
10 | (6) 50 grams or more but less than 200 grams of any | ||||||
11 | substance
containing amphetamine or any salt of an optical | ||||||
12 | isomer
of amphetamine, or an analog thereof;
| ||||||
13 | (6.5) (blank);
| ||||||
14 | (7) (i) 5 grams or more but less than 15 grams of any | ||||||
15 | substance
containing lysergic acid diethylamide (LSD), or | ||||||
16 | an analog thereof,
or (ii)
more than 10 objects or more | ||||||
17 | than 10 segregated parts of an object or objects
but less | ||||||
18 | than 15 objects or less than 15 segregated parts of an | ||||||
19 | object
containing in them or having upon them any amount of | ||||||
20 | any substance
containing lysergic acid diethylamide (LSD), | ||||||
21 | or an analog thereof;
| ||||||
22 | (7.5) (i) 5 grams or more but less than 15 grams of any | ||||||
23 | substance listed
in paragraph (1), (2), (2.1), (2.2), (3), | ||||||
24 | (14.1), (19), (20), (20.1), (21), (25), or
(26) of | ||||||
25 | subsection (d) of Section 204, or an analog or derivative | ||||||
26 | thereof, or
(ii) more than 10 pills, tablets, caplets, |
| |||||||
| |||||||
1 | capsules, or objects but less than
15 pills, tablets, | ||||||
2 | caplets, capsules, or objects containing in them or having
| ||||||
3 | upon them any amount of any substance listed in paragraph | ||||||
4 | (1), (2), (2.1),
(2.2), (3), (14.1), (19), (20), (20.1), | ||||||
5 | (21), (25), or (26) of subsection (d) of
Section 204, or an | ||||||
6 | analog or derivative thereof;
| ||||||
7 | (8) 10 grams or more but less than 30 grams of any | ||||||
8 | substance
containing pentazocine or any of the salts, | ||||||
9 | isomers and salts of isomers of
pentazocine, or an analog | ||||||
10 | thereof;
| ||||||
11 | (9) 10 grams or more but less than 30 grams of any | ||||||
12 | substance
containing methaqualone or any of the salts, | ||||||
13 | isomers and salts of isomers
of methaqualone, or an analog | ||||||
14 | thereof;
| ||||||
15 | (10) 10 grams or more but less than 30 grams of any | ||||||
16 | substance
containing phencyclidine or any of the salts, | ||||||
17 | isomers and salts of isomers
of phencyclidine (PCP), or an | ||||||
18 | analog thereof;
| ||||||
19 | (10.5) 10 grams or more but less than 30 grams of any | ||||||
20 | substance
containing ketamine or any of the salts, isomers | ||||||
21 | and salts of
isomers of ketamine, or an analog thereof;
| ||||||
22 | (10.6) 50 grams or more but less than 100 grams of any | ||||||
23 | substance containing hydrocodone, or any of the salts, | ||||||
24 | isomers and salts of isomers of hydrocodone, or an analog | ||||||
25 | thereof; | ||||||
26 | (10.7) 50 grams or more but less than 100 grams of any |
| |||||||
| |||||||
1 | substance containing dihydrocodeinone, or any of the | ||||||
2 | salts, isomers and salts of isomers of dihydrocodeinone, or | ||||||
3 | an analog thereof; | ||||||
4 | (10.8) 50 grams or more but less than 100 grams of any | ||||||
5 | substance containing dihydrocodeine, or any of the salts, | ||||||
6 | isomers and salts of isomers of dihydrocodeine, or an | ||||||
7 | analog thereof; | ||||||
8 | (10.9) 50 grams or more but less than 100 grams of any | ||||||
9 | substance containing oxycodone, or any of the salts, | ||||||
10 | isomers and salts of isomers of oxycodone, or an analog | ||||||
11 | thereof;
| ||||||
12 | (11) 50 grams or more but less than 200 grams of any | ||||||
13 | substance
containing a substance classified in Schedules I | ||||||
14 | or II, or an analog
thereof, which is not otherwise | ||||||
15 | included in this subsection.
| ||||||
16 | (c-5) (Blank).
| ||||||
17 | (d) Any person who violates this Section with regard to any | ||||||
18 | other
amount of a controlled or counterfeit substance | ||||||
19 | containing dihydrocodeinone or dihydrocodeine or classified in
| ||||||
20 | Schedules I or II, or an analog thereof, which is (i) a | ||||||
21 | narcotic
drug, (ii) lysergic acid diethylamide (LSD) or an | ||||||
22 | analog thereof,
(iii) any
substance containing amphetamine or | ||||||
23 | fentanyl or any salt or optical
isomer of amphetamine or | ||||||
24 | fentanyl, or an analog thereof, or (iv) any
substance | ||||||
25 | containing N-Benzylpiperazine (BZP) or any salt or optical
| ||||||
26 | isomer of N-Benzylpiperazine (BZP), or an analog thereof, is |
| |||||||
| |||||||
1 | guilty
of a Class 2 felony. The fine for violation of this | ||||||
2 | subsection (d) shall
not be more than $200,000.
| ||||||
3 | (d-5) (Blank).
| ||||||
4 | (e) Any person who violates this Section with regard to any | ||||||
5 | other
amount of a controlled substance other than | ||||||
6 | methamphetamine or counterfeit substance classified in
| ||||||
7 | Schedule I or II, or an analog thereof, which substance is not
| ||||||
8 | included under subsection (d) of this Section, is
guilty of a | ||||||
9 | Class 3 felony. The fine for violation of this subsection (e)
| ||||||
10 | shall not be more than $150,000.
| ||||||
11 | (f) Any person who violates this Section with regard to any | ||||||
12 | other
amount of a controlled or counterfeit substance | ||||||
13 | classified in
Schedule III is guilty of a Class 3 felony. The | ||||||
14 | fine for violation of
this subsection (f) shall not be more | ||||||
15 | than $125,000.
| ||||||
16 | (g) Any person who violates this Section with regard to any | ||||||
17 | other
amount of a controlled or counterfeit substance | ||||||
18 | classified
in Schedule IV is guilty of a Class 3 felony. The | ||||||
19 | fine for violation of
this subsection (g) shall not be more | ||||||
20 | than $100,000.
| ||||||
21 | (h) Any person who violates this Section with regard to any | ||||||
22 | other
amount of a controlled or counterfeit substance | ||||||
23 | classified in
Schedule V is guilty of a Class 3 felony. The | ||||||
24 | fine for violation of this
subsection (h) shall not be more | ||||||
25 | than $75,000.
| ||||||
26 | (i) This Section does not apply to the manufacture, |
| |||||||
| |||||||
1 | possession or
distribution of a substance in conformance with | ||||||
2 | the provisions of an approved
new drug application or an | ||||||
3 | exemption for investigational use within the
meaning of Section | ||||||
4 | 505 of the Federal Food, Drug and Cosmetic Act.
| ||||||
5 | (j) (Blank).
| ||||||
6 | (Source: P.A. 96-347, eff. 1-1-10; 97-997, eff. 1-1-13.)
| ||||||
7 | (720 ILCS 570/402) (from Ch. 56 1/2, par. 1402)
| ||||||
8 | Sec. 402. Except as otherwise authorized by this Act, it is | ||||||
9 | unlawful for
any person knowingly to possess a controlled or | ||||||
10 | counterfeit substance or controlled substance analog.
A | ||||||
11 | violation of this Act with respect to each of the controlled | ||||||
12 | substances
listed herein constitutes a single and separate | ||||||
13 | violation of this Act. For purposes of this Section, | ||||||
14 | "controlled substance analog" or "analog"
means a substance
| ||||||
15 | which is intended for human consumption , other than a | ||||||
16 | controlled substance, which is not approved by the United | ||||||
17 | States Food and Drug Administration or, if approved, is not | ||||||
18 | dispensed or possessed in accordance with State or federal law, | ||||||
19 | and
that has a chemical structure substantially similar to that | ||||||
20 | of a controlled
substance in Schedule I or II, or that was | ||||||
21 | specifically designed to produce
an effect substantially | ||||||
22 | similar to that of a controlled substance in Schedule
I or II. | ||||||
23 | Examples of chemical classes in which controlled substance | ||||||
24 | analogs
are found include, but are not limited to, the | ||||||
25 | following: phenethylamines,
N-substituted piperidines, |
| |||||||
| |||||||
1 | morphinans, ecgonines, quinazolinones, substituted
indoles, | ||||||
2 | and arylcycloalkylamines. For purposes of this Act, a | ||||||
3 | controlled
substance analog shall be treated in the same manner | ||||||
4 | as the controlled
substance to which it is substantially | ||||||
5 | similar.
| ||||||
6 | (a) Any person who violates this Section with respect to | ||||||
7 | the following
controlled or counterfeit substances and | ||||||
8 | amounts, notwithstanding any of the
provisions of subsections | ||||||
9 | (c) and (d) to the
contrary, is guilty of a Class 1 felony and | ||||||
10 | shall, if sentenced to a term
of imprisonment, be sentenced as | ||||||
11 | provided in this subsection (a) and fined
as provided in | ||||||
12 | subsection (b):
| ||||||
13 | (1) (A) not less than 4 years and not more than 15 | ||||||
14 | years with respect
to 15 grams or more but less than | ||||||
15 | 100 grams of a substance containing heroin;
| ||||||
16 | (B) not less than 6 years and not more than 30 | ||||||
17 | years with respect to 100
grams or more but less than | ||||||
18 | 400 grams of a substance containing heroin;
| ||||||
19 | (C) not less than 8 years and not more than 40 | ||||||
20 | years with respect to 400
grams or more but less than | ||||||
21 | 900 grams of any substance containing heroin;
| ||||||
22 | (D) not less than 10 years and not more than 50 | ||||||
23 | years with respect to
900 grams or more of any | ||||||
24 | substance containing heroin;
| ||||||
25 | (2) (A) not less than 4 years and not more than 15 | ||||||
26 | years with respect
to 15 grams or more but less than |
| |||||||
| |||||||
1 | 100 grams of any substance containing
cocaine;
| ||||||
2 | (B) not less than 6 years and not more than 30 | ||||||
3 | years with respect to 100
grams or more but less than | ||||||
4 | 400 grams of any substance containing cocaine;
| ||||||
5 | (C) not less than 8 years and not more than 40 | ||||||
6 | years with respect to 400
grams or more but less than | ||||||
7 | 900 grams of any substance containing cocaine;
| ||||||
8 | (D) not less than 10 years and not more than 50 | ||||||
9 | years with respect to
900 grams or more of any | ||||||
10 | substance containing cocaine;
| ||||||
11 | (3) (A) not less than 4 years and not more than 15 | ||||||
12 | years with respect
to 15 grams or more but less than | ||||||
13 | 100 grams of any substance containing
morphine;
| ||||||
14 | (B) not less than 6 years and not more than 30 | ||||||
15 | years with respect to 100
grams or more but less than | ||||||
16 | 400 grams of any substance containing morphine;
| ||||||
17 | (C) not less than 6 years and not more than 40 | ||||||
18 | years with respect to 400
grams or more but less than | ||||||
19 | 900 grams of any substance containing morphine;
| ||||||
20 | (D) not less than 10 years and not more than 50 | ||||||
21 | years with respect to
900 grams or more of any | ||||||
22 | substance containing morphine;
| ||||||
23 | (4) 200 grams or more of any substance containing | ||||||
24 | peyote;
| ||||||
25 | (5) 200 grams or more of any substance containing a | ||||||
26 | derivative of
barbituric acid or any of the salts of a |
| |||||||
| |||||||
1 | derivative of barbituric acid;
| ||||||
2 | (6) 200 grams or more of any substance containing | ||||||
3 | amphetamine or any salt
of an optical isomer of | ||||||
4 | amphetamine;
| ||||||
5 | (6.5) (blank);
| ||||||
6 | (7) (A) not less than 4 years and not more than 15 | ||||||
7 | years with respect
to: (i) 15 grams or more but less | ||||||
8 | than 100 grams of any substance containing
lysergic | ||||||
9 | acid diethylamide (LSD), or an analog thereof, or (ii) | ||||||
10 | 15 or
more objects or 15 or more segregated parts of an | ||||||
11 | object or objects but
less than 200 objects or 200 | ||||||
12 | segregated parts of an object or objects
containing in | ||||||
13 | them or having upon them any amount of any substance
| ||||||
14 | containing lysergic acid diethylamide (LSD), or an | ||||||
15 | analog thereof;
| ||||||
16 | (B) not less than 6 years and not more than 30 | ||||||
17 | years with respect
to: (i) 100 grams or more but less | ||||||
18 | than 400 grams of any substance
containing lysergic | ||||||
19 | acid diethylamide (LSD), or an analog thereof, or (ii)
| ||||||
20 | 200 or more objects or 200 or more segregated parts of | ||||||
21 | an object or objects
but less than 600 objects or less | ||||||
22 | than 600 segregated parts of an object or
objects | ||||||
23 | containing in them or having upon them any amount of | ||||||
24 | any substance
containing lysergic acid diethylamide | ||||||
25 | (LSD), or an analog thereof;
| ||||||
26 | (C) not less than 8 years and not more than 40 |
| |||||||
| |||||||
1 | years with respect
to: (i) 400 grams or more but less | ||||||
2 | than 900 grams of any substance
containing lysergic | ||||||
3 | acid diethylamide (LSD), or an analog thereof, or (ii)
| ||||||
4 | 600 or more objects or 600 or more segregated parts of | ||||||
5 | an object or objects
but less than 1500 objects or 1500 | ||||||
6 | segregated parts of an object or objects
containing in | ||||||
7 | them or having upon them any amount of any substance
| ||||||
8 | containing lysergic acid diethylamide (LSD), or an | ||||||
9 | analog thereof;
| ||||||
10 | (D) not less than 10 years and not more than 50 | ||||||
11 | years with respect
to: (i) 900 grams or more of any | ||||||
12 | substance containing lysergic acid
diethylamide (LSD), | ||||||
13 | or an analog thereof, or (ii) 1500 or more objects or
| ||||||
14 | 1500 or more segregated parts of an object or objects | ||||||
15 | containing in them or
having upon them any amount of a | ||||||
16 | substance containing lysergic acid
diethylamide (LSD), | ||||||
17 | or an analog thereof;
| ||||||
18 | (7.5) (A) not less than 4 years and not more than 15 | ||||||
19 | years with respect
to: (i) 15
grams or more but
less | ||||||
20 | than 100 grams of any substance listed in paragraph | ||||||
21 | (1), (2), (2.1), (2.2), (3),
(14.1), (19),
(20), | ||||||
22 | (20.1), (21), (25), or (26) of subsection (d) of | ||||||
23 | Section 204, or an
analog or derivative
thereof, or | ||||||
24 | (ii) 15 or more pills, tablets, caplets, capsules, or | ||||||
25 | objects but
less than 200 pills,
tablets, caplets, | ||||||
26 | capsules, or objects containing in them or having upon |
| |||||||
| |||||||
1 | them
any amount of any
substance listed in paragraph | ||||||
2 | (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), | ||||||
3 | (20.1),
(21), (25), or (26) of
subsection (d) of | ||||||
4 | Section 204, or an analog or derivative thereof;
| ||||||
5 | (B) not less than 6 years and not more than 30 | ||||||
6 | years with respect to: (i)
100
grams or more but
less | ||||||
7 | than 400 grams of any substance listed in paragraph | ||||||
8 | (1), (2), (2.1), (2.2), (3),
(14.1), (19), (20),
| ||||||
9 | (20.1), (21), (25), or (26) of subsection (d) of | ||||||
10 | Section 204, or an analog or
derivative thereof, or
| ||||||
11 | (ii) 200 or more pills, tablets, caplets, capsules, or | ||||||
12 | objects but less than
600
pills, tablets,
caplets, | ||||||
13 | capsules, or objects containing in them or having upon | ||||||
14 | them any amount
of any
substance
listed in paragraph | ||||||
15 | (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), | ||||||
16 | (20.1), (21),
(25), or (26) of subsection
(d) of | ||||||
17 | Section 204, or an analog or derivative thereof;
| ||||||
18 | (C) not less than 8 years and not more than 40 | ||||||
19 | years with respect to: (i)
400
grams or more but
less | ||||||
20 | than 900 grams of any substance listed in paragraph | ||||||
21 | (1), (2), (2.1), (2.2), (3),
(14.1), (19), (20),
| ||||||
22 | (20.1), (21), (25), or (26) of subsection (d) of | ||||||
23 | Section 204, or an analog or
derivative thereof,
or | ||||||
24 | (ii) 600 or more pills, tablets, caplets, capsules, or | ||||||
25 | objects but less than
1,500 pills, tablets,
caplets, | ||||||
26 | capsules, or objects containing in them or having upon |
| |||||||
| |||||||
1 | them any amount
of any
substance listed in paragraph | ||||||
2 | (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), | ||||||
3 | (20.1),
(21), (25), or (26) of
subsection (d) of | ||||||
4 | Section 204, or an analog or derivative thereof;
| ||||||
5 | (D) not less than 10 years and not more than 50 | ||||||
6 | years with respect to:
(i)
900 grams or more of
any | ||||||
7 | substance listed in paragraph (1), (2), (2.1), (2.2), | ||||||
8 | (3), (14.1), (19), (20),
(20.1), (21), (25), or (26)
of | ||||||
9 | subsection (d) of Section 204, or an analog or | ||||||
10 | derivative thereof, or (ii)
1,500 or more pills,
| ||||||
11 | tablets, caplets, capsules, or objects containing in | ||||||
12 | them or having upon them
any amount of a
substance | ||||||
13 | listed in paragraph (1), (2), (2.1), (2.2), (3), | ||||||
14 | (14.1), (19), (20), (20.1),
(21), (25), or (26) of
| ||||||
15 | subsection (d) of Section 204, or an analog or | ||||||
16 | derivative thereof;
| ||||||
17 | (8) 30 grams or more of any substance containing | ||||||
18 | pentazocine or any of
the salts, isomers and salts of | ||||||
19 | isomers of pentazocine, or an analog thereof;
| ||||||
20 | (9) 30 grams or more of any substance containing | ||||||
21 | methaqualone or any
of the salts, isomers and salts of | ||||||
22 | isomers of methaqualone;
| ||||||
23 | (10) 30 grams or more of any substance containing | ||||||
24 | phencyclidine or any
of the salts, isomers and salts of | ||||||
25 | isomers of phencyclidine (PCP);
| ||||||
26 | (10.5) 30 grams or more of any substance containing |
| |||||||
| |||||||
1 | ketamine or any of
the salts, isomers and salts of isomers | ||||||
2 | of ketamine;
| ||||||
3 | (11) 200 grams or more of any substance containing any | ||||||
4 | substance
classified as a narcotic drug in Schedules I or | ||||||
5 | II, or an analog thereof, which is not otherwise
included | ||||||
6 | in this subsection.
| ||||||
7 | (b) Any person sentenced with respect to violations of | ||||||
8 | paragraph (1),
(2), (3), (7), or (7.5) of subsection (a) | ||||||
9 | involving 100
grams or more of the
controlled substance named | ||||||
10 | therein, may in addition to the penalties
provided therein, be | ||||||
11 | fined an amount not to exceed $200,000 or the full
street value | ||||||
12 | of the controlled or counterfeit substances, whichever is
| ||||||
13 | greater. The term "street value" shall have the meaning
| ||||||
14 | ascribed in Section 110-5 of the Code of Criminal Procedure of | ||||||
15 | 1963. Any
person sentenced with respect to any other provision | ||||||
16 | of subsection (a), may
in addition to the penalties provided | ||||||
17 | therein, be fined an amount not to
exceed $200,000.
| ||||||
18 | (c) Any person who violates this Section with regard to an | ||||||
19 | amount
of a controlled substance other than methamphetamine or | ||||||
20 | counterfeit substance not set forth in
subsection (a) or (d) is | ||||||
21 | guilty of a Class 4 felony. The fine for a
violation punishable | ||||||
22 | under this subsection (c) shall not be more
than $25,000.
| ||||||
23 | (d) Any person who violates this Section with regard to any | ||||||
24 | amount of
anabolic steroid is guilty of a Class C misdemeanor
| ||||||
25 | for the first offense and a Class B misdemeanor for a | ||||||
26 | subsequent offense
committed within 2 years of a prior |
| |||||||
| |||||||
1 | conviction.
| ||||||
2 | (Source: P.A. 95-331, eff. 8-21-07; 96-347, eff. 1-1-10.)
|